CANVAS

Mendelian MONDO:0044720 Pathograph 22 Show in embeddings browser Hereditary Ataxia

CANVAS is a late-onset, autosomal recessive neurodegenerative disorder caused by a biallelic intronic pentanucleotide repeat expansion in RFC1, most commonly (AAGGG)n replacing the reference (AAAAG)n within the poly(A) tail of an AluSx3 element in intron 2. It is defined by the convergence of three independent balance-control deficits — cerebellar degeneration, bilateral vestibular areflexia, and a sensory neuronopathy — producing a triple-deafferentation syndrome whose imbalance exceeds what any single deficit would cause. The peripheral lesion is mechanistically a ganglionopathy (loss of sensory neuron cell bodies in the dorsal root and cranial sensory ganglia), not a length-dependent dying-back axonopathy, and the same ganglionopathy spares the auditory ganglion, which is why hearing is preserved while vestibular function is destroyed. Chronic dry cough frequently precedes neurological onset by years to decades and is the most common early clue. The disorder is a leading identified cause of late-onset ataxia, and its pathogenic mechanism remains genuinely unresolved: the expansion does not reduce RFC1 expression in patient tissue, so an overt loss-of-function model is not supported. Because the expansion lies in an intron and is absent from the reference sequence, it is not detectable by exome sequencing or sequence-based gene panels, and requires targeted repeat testing.

Ask OpenScientist

Ask a research question about CANVAS. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
8
Pathophys.
2
Histopath.
13
Phenotypes
2
Hypotheses
2
Gaps
22
Pathograph
1
Genes
4
Medical Actions
1
References
1
Deep Research
🔗

Mappings

MONDO
MONDO:0044720 cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome
skos:exactMatch MONDO
MONDO:0044720 is the exact disease concept — an autosomal recessive syndromic cerebellar ataxia caused by variation in RFC1, characterized by late-onset cerebellar dysfunction, bilateral vestibulopathy, and axonal sensory neuropathy.
👪

Inheritance

1
Autosomal recessive HP:0000007
Biallelic pathogenic RFC1 repeat expansions are required. Because the carrier frequency of the pathogenic allele is unusually high for a recessive disorder, pseudodominance (apparent transmission across generations) is well documented and should not be mistaken for autosomal dominant inheritance.
Autosomal recessive inheritance
Show evidence (2 references)
PMID:33237689 SUPPORT Other
"RFC1 CANVAS / spectrum disorder is inherited in an autosomal recessive manner."
GeneReviews establishes autosomal recessive inheritance.
PMID:40481300 SUPPORT Human Clinical
"The carrier frequency of the pathogenic AAGGG(n) expansion was approximately 1 in 16 in controls, highlighting the potential for pseudodominant inheritance and the likelihood that RFC1-related disease is underdiagnosed."
High carrier frequency underlies the documented pseudodominance.
◈

Mechanistic Hypotheses

2
RFC1 loss of function
rfc1_loss_of_function ALTERNATIVE
Evidence balance 1 refute
The intuitive model — that the expansion reduces RFC1 protein and impairs replication-factor-C function — is not supported by the original patient-tissue data, which found RFC1 expression unaffected in both peripheral and brain tissue. This hypothesis is retained as a named alternative rather than discarded, because later work reports tissue-specific transcript reduction, so the question of a partial or cell-type-restricted loss of function is not formally closed.
Show evidence (1 reference)
PMID:30926972 REFUTE Human Clinical
"does not affect RFC1 expression in patient peripheral and brain tissue, suggesting no overt loss of function"
Directly argues against an overt loss-of-function mechanism.
Repeat-intrinsic G-quadruplex structural toxicity
repeat_structural_toxicity EMERGING
Evidence balance 1 support
The pathogenic repeat motifs, but not the benign reference motif, fold into parallel G-quadruplex structures in both DNA and RNA. These structures stall DNA replication and impair gene expression in a repeat-length-dependent manner, offering a mechanism that is intrinsic to the expanded nucleic acid rather than dependent on loss of RFC1 protein. This would also explain why the disorder is not a classical misfolding or polyglutamine repeat disease.
Pathograph links
Biallelic RFC1 Intronic Repeat Expansion -> Repeat-Intrinsic Nucleic Acid Structural Toxicity INDIRECT UNKNOWN INTERMEDIATES The expanded repeat adopts non-B-DNA/RNA secondary structure, the leading candidate for how the lesion becomes pathogenic without reducing RFC1 protein.
Repeat-Intrinsic Nucleic Acid Structural Toxicity -> Dorsal Root Ganglion Sensory Neuronopathy INDIRECT UNKNOWN INTERMEDIATES Selective vulnerability of sensory ganglion neurons to the expanded repeat. The intermediate steps linking the molecular lesion to this specific cellular target are not established, and no animal model fully reproduces the human syndrome.
Repeat-Intrinsic Nucleic Acid Structural Toxicity -> Cranial Sensory Ganglionopathy INDIRECT UNKNOWN INTERMEDIATES The same selective ganglionic vulnerability extends to the vestibular, trigeminal, and geniculate ganglia.
Repeat-Intrinsic Nucleic Acid Structural Toxicity -> Autonomic Ganglion Involvement INDIRECT UNKNOWN INTERMEDIATES Autonomic dysfunction is one of the five recognised components of the RFC1 spectrum. Localising it to the autonomic ganglia is an inference by analogy with the demonstrated sensory ganglionopathy, not a directly demonstrated lesion, and is flagged as such.
Repeat-Intrinsic Nucleic Acid Structural Toxicity -> Vagal Afferent Cough Reflex Hypersensitivity INDIRECT UNKNOWN INTERMEDIATES The same selective sensory-ganglion vulnerability extends to vagal and laryngeal afferents, producing the cough arm of the disorder. This arm is wired from the molecular lesion rather than from the somatic sensory ganglionopathy because it involves a distinct afferent population and can present in isolation, decades before any balance deficit.
Repeat-Intrinsic Nucleic Acid Structural Toxicity -> Cerebellar Purkinje Cell Loss INDIRECT UNKNOWN INTERMEDIATES Purkinje neurons are a third selectively vulnerable population, degenerating predominantly in the vermis.
Show evidence (1 reference)
PMID:38266156 SUPPORT In Vitro
"The pathogenic AAGGG repeats, but not the nonpathogenic AAAAG repeats, form G4 structures to stall DNA replication and reduce gene expression via impairing the translation process in a repeat-length-dependent manner."
Structural and functional evidence for a repeat-intrinsic G-quadruplex mechanism.
?

Discussions and Knowledge Gaps

2
How does a biallelic intronic repeat expansion cause selective degeneration of sensory ganglion and Purkinje neurons when it does not reduce RFC1 expression?
KNOWLEDGE GAP OPEN canvas_mechanism_unresolved
Attached to
pathophysiology#Repeat-Intrinsic Nucleic Acid Structural Toxicity
This is the central unresolved question of the disorder. The original patient-tissue work found RFC1 expression unaffected in peripheral and brain tissue, which removes the obvious loss-of-function explanation. In vitro structural work shows the pathogenic motif forms G-quadruplexes that stall replication, but it is not obvious why a replication-associated mechanism would selectively kill post-mitotic neurons, nor why it targets sensory ganglia and Purkinje cells specifically while sparing the adjacent auditory ganglion. The exquisite selectivity of the cell loss is itself the strongest constraint on any candidate mechanism.
Proposed experiments
Ganglion-resolved RFC1 expression comparison
canvas_ganglion_resolved_rfc1_expression
Compare RFC1 transcript and protein levels directly in affected dorsal root and vestibular ganglion neurons versus the spared auditory ganglion from the same donors, to test whether a cell-type-restricted loss of function explains the selectivity that bulk-tissue measurement missed.
Decision criterion
A reduction confined to affected ganglia would revive a loss-of-function model; equal levels across affected and spared ganglia would further favour a repeat-intrinsic mechanism.
G-quadruplex modulation in patient-derived sensory neurons
canvas_g4_modulation_sensory_neurons
Test whether G-quadruplex-stabilising or -resolving interventions modify neuronal phenotypes in patient-derived sensory neurons.
Decision criterion
Phenotype rescue by G4 resolution would support the structural-toxicity hypothesis and nominate a druggable target.
Replication-independent repeat toxicity assay
canvas_replication_independent_toxicity
Determine whether the repeat produces R-loops in post-mitotic neurons, which would provide a route to toxicity that does not require DNA replication. The RNA-foci arm of this question is deliberately excluded: Cortese et al. already looked for sense and antisense repeat foci in patient brain and did not find them, which narrows the search rather than leaving it open.
Decision criterion
Detection of R-loops in non-dividing neurons would resolve the paradox of a replication-associated gene causing post-mitotic neuronal death; their absence would, together with the published negative foci result, argue against the whole class of RNA-mediated toxicity models.
Show evidence (1 reference)
PMID:30926972 SUPPORT Human Clinical
"We did not observe in patient brains the presence of RNA foci of either the sense or antisense repeated unit."
Published negative result for repeat RNA foci in patient brain, which is why this experiment is scoped to R-loops only.
Show evidence (1 reference)
PMID:30926972 SUPPORT Human Clinical
"does not affect RFC1 expression in patient peripheral and brain tissue, suggesting no overt loss of function"
Establishes the gap by ruling out the obvious loss-of-function mechanism.
Should the peripheral lesion of CANVAS be modeled as a ganglionopathy rather than conforming to the length-dependent peripheral axonal degeneration module?
INTERPRETATION OPEN canvas_ganglionopathy_not_axonopathy
Attached to
pathophysiology#Dorsal Root Ganglion Sensory Neuronopathy
The dismech module `peripheral_axonal_degeneration` explicitly models length-dependent, distal-to-proximal dying-back degeneration producing a glove-and-stocking gradient. CANVAS is mechanistically the opposite: the primary event is loss of the sensory neuron cell body in the ganglion, with tract degeneration secondary, and the resulting sensory loss is not length-dependent. This entry therefore deliberately does not declare conformance to that module, even though CANVAS would superficially match on the phenotype of peripheral sensory loss. Conformance is declared only to `cerebellar_purkinje_degeneration`, where the mechanism genuinely matches. A future ganglionopathy/sensory-neuronopathy module would be the correct home for this pattern, which is shared with paraneoplastic sensory neuronopathy, Sjogren ganglionopathy, and pyridoxine toxicity.
Flagged as a candidate new mechanism module rather than forcing a conformance that would misrepresent the mechanism.
⚙

Pathophysiology

8
Biallelic RFC1 Intronic Repeat Expansion
A biallelic expansion of a pentanucleotide repeat in intron 2 of RFC1, sitting in the poly(A) tail of an AluSx3 element. The expanded motif differs from the reference (AAAAG)11 allele in both length and sequence. Because the pathogenic repeat is absent from the reference genome and lies within an intron, it is invisible to exome sequencing and to sequence-based gene panels.
Repeat-intrinsic G-quadruplex structural toxicity
RFC1 hgnc:9969
Downstream
Repeat-Intrinsic Nucleic Acid Structural Toxicity The expanded repeat adopts non-B-DNA/RNA secondary structure, the leading candidate for how the lesion becomes pathogenic without reducing RFC1 protein. Repeat-intrinsic G-quadruplex structural toxicity
Show evidence (1 reference)
PMID:30926972 SUPPORT Human Clinical
"The expansion, which occurs in the poly(A) tail of an AluSx3 element and differs in both size and nucleotide sequence from the reference (AAAAG)11 allele, does not affect RFC1 expression in patient peripheral and brain tissue, suggesting no overt loss of function."
Establishes the molecular lesion and its location in the AluSx3 poly(A) tail.
Repeat-Intrinsic Nucleic Acid Structural Toxicity
The pathogenic repeat folds into parallel G-quadruplex structures in DNA and RNA, stalling DNA replication and impairing gene expression in a repeat-length-dependent manner. The benign reference repeat does not form these structures, making the structural difference — rather than a change in RFC1 protein level — the candidate proximate cause.
Repeat-intrinsic G-quadruplex structural toxicity
Downstream
Dorsal Root Ganglion Sensory Neuronopathy Selective vulnerability of sensory ganglion neurons to the expanded repeat. The intermediate steps linking the molecular lesion to this specific cellular target are not established, and no animal model fully reproduces the human syndrome. Repeat-intrinsic G-quadruplex structural toxicity
Cranial Sensory Ganglionopathy The same selective ganglionic vulnerability extends to the vestibular, trigeminal, and geniculate ganglia. Repeat-intrinsic G-quadruplex structural toxicity
Autonomic Ganglion Involvement Autonomic dysfunction is one of the five recognised components of the RFC1 spectrum. Localising it to the autonomic ganglia is an inference by analogy with the demonstrated sensory ganglionopathy, not a directly demonstrated lesion, and is flagged as such. Repeat-intrinsic G-quadruplex structural toxicity
Vagal Afferent Cough Reflex Hypersensitivity The same selective sensory-ganglion vulnerability extends to vagal and laryngeal afferents, producing the cough arm of the disorder. This arm is wired from the molecular lesion rather than from the somatic sensory ganglionopathy because it involves a distinct afferent population and can present in isolation, decades before any balance deficit. Repeat-intrinsic G-quadruplex structural toxicity
Cerebellar Purkinje Cell Loss Purkinje neurons are a third selectively vulnerable population, degenerating predominantly in the vermis. Repeat-intrinsic G-quadruplex structural toxicity
Show evidence (1 reference)
PMID:38266156 SUPPORT In Vitro
"The pathogenic AAGGG repeats, but not the nonpathogenic AAAAG repeats, form G4 structures to stall DNA replication and reduce gene expression via impairing the translation process in a repeat-length-dependent manner."
Pathogenic-versus-benign motif comparison supports a structural mechanism.
Dorsal Root Ganglion Sensory Neuronopathy
Loss of sensory neuron cell bodies within the dorsal root ganglia, with secondary degeneration of the central posterior column tracts. This is a ganglionopathy (neuronopathy), not a length-dependent dying-back axonopathy — a distinction that explains the non-length-dependent, often asymmetric sensory loss and the absence of a glove-and-stocking gradient.
dorsal root ganglion sensory neuron CL:1001451 ↓ DECREASED
Downstream
Impaired proprioception Loss of large-fiber proprioceptive afferents deprives balance control of position sense.
Sensory ataxia Proprioceptive deafferentation produces sensory ataxia independent of the cerebellar deficit.
Sensory neuropathy Ganglionic neuronal loss manifests electrophysiologically as reduced or absent sensory nerve action potentials, in a non-length-dependent distribution.
Areflexia Loss of the afferent limb of the monosynaptic stretch reflex abolishes tendon reflexes.
Multisensory Balance Failure Proprioceptive loss removes one of the three balance-control channels.
Show evidence (2 references)
PMID:24682971 SUPPORT Human Clinical
"Spinal cord pathology demonstrated a marked dorsal root ganglionopathy with secondary tract degeneration."
Post-mortem evidence for dorsal root ganglionopathy with secondary tract degeneration.
PMID:24682971 SUPPORT Human Clinical
"The likely underlying sensory pathology in CANVAS is loss of neurons from the dorsal root and V, VII, and VIII cranial nerve ganglia"
Establishes neuronal cell-body loss as the sensory lesion, i.e. a neuronopathy.
Cranial Sensory Ganglionopathy
Severe loss of vestibular ganglion neurons with atrophy of the vestibular nerves, while vestibular hair cells and vestibular nuclei are preserved — the lesion is the first-order neuron, not the end organ or the central relay. The trigeminal and geniculate ganglia degenerate too, whereas the auditory ganglion is relatively spared, which is the anatomical basis for the clinically characteristic combination of destroyed vestibular function with normal hearing.
vestibular ganglion neuron CL:0000101 ↓ DECREASED
Downstream
Vestibular areflexia Loss of vestibular first-order neurons abolishes the vestibulo-ocular reflex bilaterally.
Oscillopsia Failure of the vestibulo-ocular reflex prevents gaze stabilization during head motion, producing apparent movement of the visual scene.
Multisensory Balance Failure Vestibular loss removes a second balance-control channel.
Show evidence (2 references)
PMID:33492056 SUPPORT Human Clinical
"All five temporal bones showed severe loss of vestibular ganglion cells (cell counts 3-16% of normal), and atrophy of the vestibular nerves, whereas vestibular receptor hair cells and the vestibular nuclei were preserved."
Localizes the vestibular lesion to the ganglion with sparing of hair cells and nuclei.
PMID:33492056 SUPPORT Human Clinical
"In contrast, auditory receptor hair cells, the auditory ganglia (cell counts 51-100% of normal), and the auditory nerves were relatively preserved."
Documents auditory sparing, explaining preserved hearing.
Autonomic Ganglion Involvement
Dysautonomia — orthostatic hypotension, erectile dysfunction, and bowel and bladder disturbance — is one of the five recognised components of the RFC1 spectrum. It is clinically important beyond its own morbidity because it is a principal reason CANVAS is mistaken for multiple system atrophy, from which it is distinguished by its far slower course. Whether the lesion sits in the autonomic ganglia themselves is inferred from the demonstrated sensory ganglionopathy rather than directly shown, and is recorded here as an inference.
Downstream
Autonomic dysfunction Autonomic involvement manifests as orthostatic, sexual, bowel, and bladder dysfunction.
Show evidence (1 reference)
PMID:33237689 SUPPORT Other
"(4) autonomic dysfunction; and (5) cough"
GeneReviews lists autonomic dysfunction as a component of the RFC1 spectrum.
Vagal Afferent Cough Reflex Hypersensitivity
Chronic dry cough is attributed to sensory neuronopathy affecting vagal and laryngeal afferents, producing a neurogenic cough with heightened cough reflex sensitivity. Because this arm involves a different sensory ganglion population from the balance pathways, it can present in isolation and typically precedes the neurological features by years to decades.
Downstream
Chronic cough Cough reflex hypersensitivity manifests as a chronic dry cough that is typically refractory to conventional antitussive management.
Show evidence (1 reference)
PMID:39811557 SUPPORT Human Clinical
"RFC1++ participants had heightened cough reflex sensitivity to capsaicin, similar to previous CANVAS and RCC studies."
Demonstrates cough reflex hypersensitivity in biallelic RFC1 expansion carriers.
Cerebellar Purkinje Cell Loss
Degeneration of cerebellar Purkinje neurons, predominantly in the vermis, which is the anatomical correlate of the vermian atrophy seen on MRI and of the cerebellar component of the ataxia.
Purkinje cell CL:0000121 ↓ DECREASED
Downstream
Cerebellar atrophy Purkinje neuron loss produces the vermis-predominant cerebellar atrophy seen on imaging.
Progressive cerebellar ataxia Loss of cerebellar cortical output produces gait and limb ataxia.
Dysphagia Bulbar and cerebellar incoordination impairs swallowing, and the resulting aspiration risk is an explicit surveillance target in the GeneReviews management guidance.
Dysarthria Cerebellar degeneration impairs the coordination of speech musculature.
Multisensory Balance Failure Cerebellar degeneration removes the third balance-control channel.
Show evidence (1 reference)
PMID:24682971 SUPPORT Human Clinical
"Cerebellar pathology showed loss of Purkinje cells, predominantly in the vermis."
Post-mortem evidence of vermis-predominant Purkinje cell loss.
Multisensory Balance Failure
The clinically defining feature of CANVAS is that all three systems used to stabilise posture and gaze — proprioception, vestibular input, and cerebellar processing — fail together. Because each system normally compensates for loss of the others, their simultaneous failure produces imbalance disproportionate to any single deficit. This triple-deafferentation is why CANVAS causes greater disability than an isolated sensory neuronopathy, isolated vestibulopathy, or isolated cerebellar degeneration of comparable individual severity.
Downstream
Progressive gait imbalance and falls Loss of all three balance channels produces progressive unsteadiness and a high falls risk, the dominant source of disability.
Show evidence (1 reference)
PMID:33492056 SUPPORT Human Clinical
"characterized by progressive imbalance due to a combination of cerebellar, somatosensory, and selective vestibular impairment with normal hearing"
States explicitly that the imbalance arises from the combination of the three impairments.
✶

Histopathology

2
Sensory ganglion neuronal loss
Marked neuronal loss in the dorsal root ganglia with secondary degeneration of the posterior column tracts, and severe depletion of vestibular ganglion cells (3-16% of normal counts) with preserved vestibular hair cells and nuclei. The trigeminal and geniculate ganglia are also affected while the auditory ganglion is relatively preserved.
Show evidence (2 references)
PMID:33492056 SUPPORT Human Clinical
"All five temporal bones showed severe loss of vestibular ganglion cells (cell counts 3-16% of normal), and atrophy of the vestibular nerves, whereas vestibular receptor hair cells and the vestibular nuclei were preserved."
Quantitative histopathology of the vestibular ganglionopathy.
PMID:24682971 SUPPORT Human Clinical
"Spinal cord pathology demonstrated a marked dorsal root ganglionopathy with secondary tract degeneration."
Spinal histopathology of the dorsal root ganglionopathy.
Cerebellar Purkinje cell depletion
Loss of Purkinje cells with a vermis predominance.
Show evidence (1 reference)
PMID:24682971 SUPPORT Human Clinical
"Cerebellar pathology showed loss of Purkinje cells, predominantly in the vermis."
Cerebellar histopathology.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for CANVAS Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

13
Digestive 1
Dysphagia Dysphagia HP:0002015
Show evidence (1 reference)
PMID:33237689 PARTIAL Other
"aspiration risk and feeding methods"
GeneReviews surveillance of aspiration risk and feeding implies clinically significant dysphagia; the phenotype is inferred from the management text, hence PARTIAL.
Eye 1
Oscillopsia Oscillopsia HP:0034773
Show evidence (1 reference)
PMID:33492056 PARTIAL Human Clinical
"severe, bilateral, symmetrical, selective loss of vestibular function"
Supports the bilateral vestibular loss that causes oscillopsia; the symptom itself is inferred, hence PARTIAL.
Nervous System 6
Progressive cerebellar ataxia FREQUENT Progressive cerebellar ataxia HP:0002073
Course: PROGRESSIVE
Show evidence (2 references)
PMID:37301658 SUPPORT Human Clinical
"CANVAS is a clinical entity associating cerebellar ataxia, sensory neuronopathy and vestibular areflexia due to biallelic expansions in RFC1."
Establishes cerebellar ataxia as a defining feature.
PMID:33237689 SUPPORT Other
"In a retrospective study of 100 affected individuals after ten years of disease duration, two thirds had clinical features of CANVAS; 16 had a complex sensory ataxia with cerebellar or vestibular involvement; and 15 had a sensory neuropathy as the only clinically detectable manifestation"
Derived count: of 100 individuals, 66 had the full triad and a further 16 had cerebellar or vestibular involvement, bounding cerebellar involvement at 66-82% and placing it in the FREQUENT (30-79%) band, which covers most of that interval.
Sensory neuropathy Sensory neuropathy HP:0000763
Show evidence (2 references)
PMID:33237689 SUPPORT Other
"15 had a sensory neuropathy as the only clinically detectable manifestation"
Sensory neuropathy can be the sole manifestation of the spectrum.
PMID:41964406 SUPPORT Human Clinical
"These data indicate that motor nerve involvement should not exclude patients from RFC1 repeat screening."
Motor involvement does not exclude RFC1-related disease.
Areflexia Areflexia HP:0001284
Show evidence (1 reference)
PMID:24682971 PARTIAL Human Clinical
"The likely underlying sensory pathology in CANVAS is loss of neurons from the dorsal root and V, VII, and VIII cranial nerve ganglia"
Supports dorsal root ganglion neuronal loss; areflexia as its reflex-arc consequence is inferred, hence PARTIAL.
Autonomic dysfunction Abnormal autonomic nervous system physiology HP:0012332
Show evidence (1 reference)
PMID:33237689 SUPPORT Other
"(4) autonomic dysfunction; and (5) cough"
GeneReviews lists autonomic dysfunction as a component of the RFC1 spectrum.
Dysarthria Dysarthria HP:0001260
Show evidence (1 reference)
PMID:33237689 PARTIAL Other
"typical cerebellar ataxia, neuropathy, vestibular areflexia syndrome (CANVAS)"
Supports the cerebellar syndrome of which dysarthria is a component; the specific feature is inferred, hence PARTIAL.
Cerebellar atrophy Cerebellar atrophy HP:0001272
Show evidence (1 reference)
PMID:24682971 SUPPORT Human Clinical
"Cerebellar pathology showed loss of Purkinje cells, predominantly in the vermis."
Neuropathological basis of the vermis-predominant atrophy.
Respiratory 1
Chronic cough FREQUENT Chronic cough HP:0034315
Temporal: CHRONIC
Show evidence (2 references)
PMID:37301658 SUPPORT Human Clinical
"The clinical picture showed that chronic cough was a frequent sign beginning before the onset of other symptoms."
Documents chronic cough preceding the other manifestations, and supplies the qualitative frequency term ("a frequent sign") that maps to the FREQUENT (30-79%) band under the frequency-evidence SOP.
PMID:39811557 SUPPORT Human Clinical
"Biallelic RFC1 repeat expansions (RFC1++) were present in 8% of RCC patients."
Quantifies biallelic RFC1 expansion among refractory chronic cough patients.
Other 4
Vestibular areflexia FREQUENT Vestibular areflexia HP:0008568
Show evidence (2 references)
PMID:33492056 SUPPORT Human Clinical
"severe, bilateral, symmetrical, selective loss of vestibular function"
Documents the bilateral selective vestibular loss.
PMID:33237689 SUPPORT Other
"In a retrospective study of 100 affected individuals after ten years of disease duration, two thirds had clinical features of CANVAS; 16 had a complex sensory ataxia with cerebellar or vestibular involvement; and 15 had a sensory neuropathy as the only clinically detectable manifestation"
Derived count: 66 of 100 had the full triad and a further 16 had cerebellar or vestibular involvement, bounding vestibular involvement at 66-82% and placing it in the FREQUENT (30-79%) band, which covers most of that interval.
Sensory ataxia Sensory ataxia HP:0010871
Show evidence (1 reference)
PMID:37301658 SUPPORT Human Clinical
"Sensory neuronopathies name the degeneration of peripheral sensory neurons in dorsal root ganglia."
Defines the sensory neuronopathy underlying sensory ataxia.
Impaired proprioception Impaired proprioception HP:0010831
Show evidence (1 reference)
PMID:24682971 SUPPORT Human Clinical
"Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS."
Attributes sensory impairment to the dorsal root ganglionopathy.
Progressive gait imbalance and falls Unsteady gait HP:0002317
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:33492056 SUPPORT Human Clinical
"an adult-onset recessively-inherited ataxia, characterized by progressive imbalance"
Documents progressive imbalance as the clinical course.
🧬

Genetic Associations

1
RFC1
Gene: RFC1 hgnc:9969 relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (4 references)
PMID:30926972 SUPPORT Human Clinical
"We used non-parametric linkage analysis and genome sequencing to identify a biallelic intronic AAGGG repeat expansion in the replication factor C subunit 1 (RFC1) gene as the cause of familial CANVAS and a frequent cause of late-onset ataxia, particularly if sensory neuronopathy and bilateral..."
Identifies biallelic intronic RFC1 AAGGG expansion as the cause of CANVAS.
PMID:31230722 SUPPORT Human Clinical
"a recessively inherited, ancient RE located in intron 2 of RFC1 is the predominant cause of CANVAS"
Independent confirmation that the intron 2 repeat expansion is the predominant cause.
PMID:32851396 SUPPORT Human Clinical
"We show a novel, possibly population-specific CANVAS configuration (AAAGG)10-25(AAGGG)exp, which was the cause of CANVAS in all patients."
Documents a population-specific founder repeat configuration.
+ 1 more reference
💊

Medical Actions

4
Multidisciplinary Supportive Care
Action: supportive care Ontology label: Supportive Care NCIT:C15747
No disease-modifying therapy exists. Management is supportive and coordinated across neurology, physical and occupational therapy, physiatry, and — as needed — speech therapy, respiratory therapy, nutrition, and gastroenterology, with the goals of maximising function and reducing complications. Surveillance covers progression of neurological findings, mobility and self-help skills, communication needs, and aspiration risk.
Show evidence (2 references)
PMID:33237689 SUPPORT Other
"The goals of treatment are to maximize function and reduce complications."
GeneReviews management principle.
PMID:33237689 SUPPORT Other
"each affected individual should be managed by a multidisciplinary team of relevant specialists such as neurologists, occupational therapists, physical therapists, physiatrists"
Supports the multidisciplinary management model.
Physical and Vestibular Rehabilitation
Action: physical therapy Ontology label: Physical Therapy NCIT:C15302
Physical and occupational therapy for gait, balance, and falls prevention. Rehabilitation is constrained in CANVAS in a way that is mechanistically informative: standard vestibular rehabilitation relies on substituting proprioceptive and visual cues for lost vestibular input, but proprioception is also lost here, which limits the usual compensation strategy.
Show evidence (1 reference)
PMID:33237689 SUPPORT Other
"occupational therapists, physical therapists, physiatrists"
GeneReviews identifies rehabilitation specialists in the care team.
Avoidance of Neurotoxic Agents
Action: supportive care Ontology label: Supportive Care NCIT:C15747
A specific and actionable management point: agents toxic to the peripheral nerves (neurotoxic chemotherapy, pyridoxine), the cerebellum (phenytoin), or the vestibular system (aminoglycosides) should be avoided, as should chronic alcohol consumption. Each of these targets a system already compromised in CANVAS, so exposure risks compounding an existing deficit.
Show evidence (1 reference)
PMID:33237689 SUPPORT Other
"Medications of known toxicity for peripheral nerves (e.g., neurotoxic chemotherapy agents, pyridoxine), the cerebellum (e.g., phenytoin), or the vestibular system (e.g., aminoglycosides); chronic alcohol consumption."
GeneReviews agents/circumstances to avoid.
Genetic Counseling
Action: genetic counseling Ontology label: Genetic Counseling NCIT:C15240
Autosomal recessive counseling with a 25% sibling recurrence risk when both parents are carriers. Counseling must address pseudodominance, since the high carrier frequency means affected individuals can appear in consecutive generations and be mistaken for dominant transmission.
Show evidence (1 reference)
PMID:33237689 SUPPORT Other
"each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier"
Recurrence risks for genetic counseling.
{ }

Source YAML

click to show 
name: CANVAS
category: Mendelian
creation_date: "2026-07-30T20:10:00Z"
synonyms:
- Cerebellar ataxia, neuropathy, and vestibular areflexia syndrome
- RFC1 CANVAS spectrum disorder
- Cerebellar ataxia with bilateral vestibulopathy syndrome
- CABV syndrome
description: >-
  CANVAS is a late-onset, autosomal recessive neurodegenerative disorder caused by
  a biallelic intronic pentanucleotide repeat expansion in RFC1, most commonly
  (AAGGG)n replacing the reference (AAAAG)n within the poly(A) tail of an AluSx3
  element in intron 2. It is defined by the convergence of three independent
  balance-control deficits — cerebellar degeneration, bilateral vestibular
  areflexia, and a sensory neuronopathy — producing a triple-deafferentation
  syndrome whose imbalance exceeds what any single deficit would cause. The
  peripheral lesion is mechanistically a ganglionopathy (loss of sensory neuron
  cell bodies in the dorsal root and cranial sensory ganglia), not a
  length-dependent dying-back axonopathy, and the same ganglionopathy spares the
  auditory ganglion, which is why hearing is preserved while vestibular function
  is destroyed. Chronic dry cough frequently precedes neurological onset by years
  to decades and is the most common early clue. The disorder is a leading
  identified cause of late-onset ataxia, and its pathogenic mechanism remains
  genuinely unresolved: the expansion does not reduce RFC1 expression in patient
  tissue, so an overt loss-of-function model is not supported. Because the
  expansion lies in an intron and is absent from the reference sequence, it is not
  detectable by exome sequencing or sequence-based gene panels, and requires
  targeted repeat testing.
disease_term:
  preferred_term: cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome
  term:
    id: MONDO:0044720
    label: cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome
parents:
- Hereditary Ataxia
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0044720
      label: cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO:0044720 is the exact disease concept — an autosomal recessive syndromic
      cerebellar ataxia caused by variation in RFC1, characterized by late-onset
      cerebellar dysfunction, bilateral vestibulopathy, and axonal sensory
      neuropathy.
references:
- reference: PMID:33237689
  title: "RFC1 CANVAS / Spectrum Disorder."
  tags:
  - GeneReviews
inheritance:
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Biallelic pathogenic RFC1 repeat expansions are required. Because the carrier
    frequency of the pathogenic allele is unusually high for a recessive disorder,
    pseudodominance (apparent transmission across generations) is well documented
    and should not be mistaken for autosomal dominant inheritance.
  evidence:
  - reference: PMID:33237689
    reference_title: "RFC1 CANVAS / Spectrum Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "RFC1 CANVAS / spectrum disorder is inherited in an autosomal recessive manner."
    explanation: GeneReviews establishes autosomal recessive inheritance.
  - reference: PMID:40481300
    reference_title: "Comprehensive Characterisation of the RFC1 Repeat in an Australian Cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The carrier frequency of the pathogenic AAGGG(n) expansion was approximately 1 in 16 in controls, highlighting the potential for pseudodominant inheritance and the likelihood that RFC1-related disease is underdiagnosed."
    explanation: High carrier frequency underlies the documented pseudodominance.
genetic:
- name: RFC1
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  gene_term:
    preferred_term: RFC1
    term:
      id: hgnc:9969
      label: RFC1
  notes: >-
    RFC1 encodes the large subunit of the replication factor C clamp-loader complex,
    which loads PCNA onto DNA. The pathogenic lesion is predominantly not a coding
    mutation but a biallelic expansion of a pentanucleotide repeat in intron 2,
    within the poly(A) tail of an AluSx3 element; truncating RFC1 point variants in
    trans with an expanded allele have also been reported, so the allelic spectrum
    is not purely repeat-based. Multiple pathogenic motifs exist and are
    population-structured: (AAGGG)n predominates in European populations, (ACAGG)n
    in Asia-Pacific populations, and a compound (AAAGG)10-25(AAGGG)exp configuration
    is a founder allele in New Zealand Maori and Cook Island Maori individuals. This
    motif heterogeneity has direct diagnostic consequences, because a repeat-primed
    PCR assay designed only for AAGGG will miss the other configurations.
  evidence:
  - reference: PMID:30926972
    reference_title: "Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We used non-parametric linkage analysis and genome sequencing to identify a biallelic intronic AAGGG repeat expansion in the replication factor C subunit 1 (RFC1) gene as the cause of familial CANVAS and a frequent cause of late-onset ataxia, particularly if sensory neuronopathy and bilateral vestibular areflexia coexist."
    explanation: Identifies biallelic intronic RFC1 AAGGG expansion as the cause of CANVAS.
  - reference: PMID:31230722
    reference_title: "Bioinformatics-Based Identification of Expanded Repeats: A Non-reference Intronic Pentamer Expansion in RFC1 Causes CANVAS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a recessively inherited, ancient RE located in intron 2 of RFC1 is the predominant cause of CANVAS"
    explanation: Independent confirmation that the intron 2 repeat expansion is the predominant cause.
  - reference: PMID:32851396
    reference_title: "A Maori specific RFC1 pathogenic repeat configuration in CANVAS, likely due to a founder allele."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We show a novel, possibly population-specific CANVAS configuration (AAAGG)10-25(AAGGG)exp, which was the cause of CANVAS in all patients."
    explanation: Documents a population-specific founder repeat configuration.
  - reference: PMID:33103729
    reference_title: "A novel RFC1 repeat motif (ACAGG) in two Asia-Pacific CANVAS families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We screened an Asian-Pacific cohort for CANVAS and identified a novel RFC1 repeat expansion motif, (ACAGG)exp, in three affected individuals."
    explanation: Documents the ACAGG pathogenic motif in Asia-Pacific families.
mechanistic_hypotheses:
- hypothesis_group_id: rfc1_loss_of_function
  hypothesis_label: RFC1 loss of function
  status: ALTERNATIVE
  description: >-
    The intuitive model — that the expansion reduces RFC1 protein and impairs
    replication-factor-C function — is not supported by the original patient-tissue
    data, which found RFC1 expression unaffected in both peripheral and brain
    tissue. This hypothesis is retained as a named alternative rather than
    discarded, because later work reports tissue-specific transcript reduction, so
    the question of a partial or cell-type-restricted loss of function is not
    formally closed.
  evidence:
  - reference: PMID:30926972
    reference_title: "Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "does not affect RFC1 expression in patient peripheral and brain tissue, suggesting no overt loss of function"
    explanation: Directly argues against an overt loss-of-function mechanism.
- hypothesis_group_id: repeat_structural_toxicity
  hypothesis_label: Repeat-intrinsic G-quadruplex structural toxicity
  status: EMERGING
  description: >-
    The pathogenic repeat motifs, but not the benign reference motif, fold into
    parallel G-quadruplex structures in both DNA and RNA. These structures stall
    DNA replication and impair gene expression in a repeat-length-dependent manner,
    offering a mechanism that is intrinsic to the expanded nucleic acid rather than
    dependent on loss of RFC1 protein. This would also explain why the disorder is
    not a classical misfolding or polyglutamine repeat disease.
  evidence:
  - reference: PMID:38266156
    reference_title: "Structural investigation of pathogenic RFC1 AAGGG pentanucleotide repeats reveals a role of G-quadruplex formation in repeat instability."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The pathogenic AAGGG repeats, but not the nonpathogenic AAAAG repeats, form G4 structures to stall DNA replication and reduce gene expression via impairing the translation process in a repeat-length-dependent manner."
    explanation: Structural and functional evidence for a repeat-intrinsic G-quadruplex mechanism.
pathophysiology:
- name: Biallelic RFC1 Intronic Repeat Expansion
  biological_scale: MOLECULAR
  description: >-
    A biallelic expansion of a pentanucleotide repeat in intron 2 of RFC1, sitting
    in the poly(A) tail of an AluSx3 element. The expanded motif differs from the
    reference (AAAAG)11 allele in both length and sequence. Because the pathogenic
    repeat is absent from the reference genome and lies within an intron, it is
    invisible to exome sequencing and to sequence-based gene panels.
  genes:
  - preferred_term: RFC1
    term:
      id: hgnc:9969
      label: RFC1
  evidence:
  - reference: PMID:30926972
    reference_title: "Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The expansion, which occurs in the poly(A) tail of an AluSx3 element and differs in both size and nucleotide sequence from the reference (AAAAG)11 allele, does not affect RFC1 expression in patient peripheral and brain tissue, suggesting no overt loss of function."
    explanation: Establishes the molecular lesion and its location in the AluSx3 poly(A) tail.
  downstream:
  - target: Repeat-Intrinsic Nucleic Acid Structural Toxicity
    description: >-
      The expanded repeat adopts non-B-DNA/RNA secondary structure, the leading
      candidate for how the lesion becomes pathogenic without reducing RFC1 protein.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - repeat_structural_toxicity
    evidence:
    - reference: PMID:38266156
      reference_title: "Structural investigation of pathogenic RFC1 AAGGG pentanucleotide repeats reveals a role of G-quadruplex formation in repeat instability."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "we report that the pathogenic RFC1 AAGGG repeats form DNA and RNA parallel G-quadruplex (G4) structures that play a role in impairing biological processes"
      explanation: Links the expansion to formation of G-quadruplex structures.
- name: Repeat-Intrinsic Nucleic Acid Structural Toxicity
  biological_scale: MOLECULAR
  description: >-
    The pathogenic repeat folds into parallel G-quadruplex structures in DNA and
    RNA, stalling DNA replication and impairing gene expression in a
    repeat-length-dependent manner. The benign reference repeat does not form these
    structures, making the structural difference — rather than a change in RFC1
    protein level — the candidate proximate cause.
  evidence:
  - reference: PMID:38266156
    reference_title: "Structural investigation of pathogenic RFC1 AAGGG pentanucleotide repeats reveals a role of G-quadruplex formation in repeat instability."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The pathogenic AAGGG repeats, but not the nonpathogenic AAAAG repeats, form G4 structures to stall DNA replication and reduce gene expression via impairing the translation process in a repeat-length-dependent manner."
    explanation: Pathogenic-versus-benign motif comparison supports a structural mechanism.
  downstream:
  - target: Dorsal Root Ganglion Sensory Neuronopathy
    description: >-
      Selective vulnerability of sensory ganglion neurons to the expanded repeat.
      The intermediate steps linking the molecular lesion to this specific cellular
      target are not established, and no animal model fully reproduces the human
      syndrome.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - repeat_structural_toxicity
    evidence:
    - reference: PMID:24682971
      reference_title: "Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "Spinal cord pathology demonstrated a marked dorsal root ganglionopathy with secondary tract degeneration."
      explanation: >-
        Establishes the dorsal root ganglionopathy as the sensory lesion; the link
        from the molecular repeat to this target is inferential, hence PARTIAL.
  - target: Cranial Sensory Ganglionopathy
    description: >-
      The same selective ganglionic vulnerability extends to the vestibular,
      trigeminal, and geniculate ganglia.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - repeat_structural_toxicity
    evidence:
    - reference: PMID:33492056
      reference_title: "The Pathology of the Vestibular System in CANVAS."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "In CANVAS there is a severe cranial sensory ganglionopathy neuronopathy (ganglionopathy) involving the vestibular, facial, and trigeminal ganglia but sparing the auditory ganglia."
      explanation: >-
        Establishes the cranial ganglionopathy; the molecular-to-cellular link is
        inferential, hence PARTIAL.
  - target: Autonomic Ganglion Involvement
    description: >-
      Autonomic dysfunction is one of the five recognised components of the RFC1
      spectrum. Localising it to the autonomic ganglia is an inference by analogy
      with the demonstrated sensory ganglionopathy, not a directly demonstrated
      lesion, and is flagged as such.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - repeat_structural_toxicity
    evidence:
    - reference: PMID:33237689
      reference_title: "RFC1 CANVAS / Spectrum Disorder."
      supports: PARTIAL
      evidence_source: OTHER
      snippet: "(4) autonomic dysfunction; and (5) cough"
      explanation: >-
        Establishes autonomic dysfunction as part of the spectrum; the ganglionic
        localisation is inferred by analogy, hence PARTIAL.
  - target: Vagal Afferent Cough Reflex Hypersensitivity
    description: >-
      The same selective sensory-ganglion vulnerability extends to vagal and
      laryngeal afferents, producing the cough arm of the disorder. This arm is
      wired from the molecular lesion rather than from the somatic sensory
      ganglionopathy because it involves a distinct afferent population and can
      present in isolation, decades before any balance deficit.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - repeat_structural_toxicity
    evidence:
    - reference: PMID:39811557
      reference_title: "Repeat expansions in RFC1 gene in refractory chronic cough."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "Biallelic RFC1 repeat expansions (RFC1++) were present in 8% of RCC patients."
      explanation: >-
        Links the biallelic expansion to refractory chronic cough; the intervening
        vagal-afferent steps are inferred, hence PARTIAL.
  - target: Cerebellar Purkinje Cell Loss
    description: >-
      Purkinje neurons are a third selectively vulnerable population, degenerating
      predominantly in the vermis.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - repeat_structural_toxicity
    evidence:
    - reference: PMID:24682971
      reference_title: "Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "Cerebellar pathology showed loss of Purkinje cells, predominantly in the vermis."
      explanation: >-
        Establishes Purkinje cell loss; the molecular-to-cellular link is
        inferential, hence PARTIAL.
- name: Dorsal Root Ganglion Sensory Neuronopathy
  biological_scale: CELLULAR
  description: >-
    Loss of sensory neuron cell bodies within the dorsal root ganglia, with
    secondary degeneration of the central posterior column tracts. This is a
    ganglionopathy (neuronopathy), not a length-dependent dying-back axonopathy —
    a distinction that explains the non-length-dependent, often asymmetric sensory
    loss and the absence of a glove-and-stocking gradient.
  cell_types:
  - preferred_term: dorsal root ganglion sensory neuron
    term:
      id: CL:1001451
      label: sensory neuron of dorsal root ganglion
    modifier: DECREASED
  evidence:
  - reference: PMID:24682971
    reference_title: "Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Spinal cord pathology demonstrated a marked dorsal root ganglionopathy with secondary tract degeneration."
    explanation: Post-mortem evidence for dorsal root ganglionopathy with secondary tract degeneration.
  - reference: PMID:24682971
    reference_title: "Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The likely underlying sensory pathology in CANVAS is loss of neurons from the dorsal root and V, VII, and VIII cranial nerve ganglia"
    explanation: Establishes neuronal cell-body loss as the sensory lesion, i.e. a neuronopathy.
  downstream:
  - target: Impaired proprioception
    description: Loss of large-fiber proprioceptive afferents deprives balance control of position sense.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24682971
      reference_title: "Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS."
      explanation: Attributes the sensory impairment directly to the ganglionopathy.
  - target: Sensory ataxia
    description: Proprioceptive deafferentation produces sensory ataxia independent of the cerebellar deficit.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Loss of proprioceptive afferent input to spinal and cerebellar balance circuits
    evidence:
    - reference: PMID:37301658
      reference_title: "CANVAS, a sensory neuronopathy to look for in ataxia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "CANVAS is a clinical entity associating cerebellar ataxia, sensory neuronopathy and vestibular areflexia due to biallelic expansions in RFC1."
      explanation: Establishes sensory neuronopathy as a defining component of the syndrome.
  - target: Sensory neuropathy
    description: >-
      Ganglionic neuronal loss manifests electrophysiologically as reduced or absent
      sensory nerve action potentials, in a non-length-dependent distribution.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37301658
      reference_title: "CANVAS, a sensory neuronopathy to look for in ataxia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Sensory neuronopathies name the degeneration of peripheral sensory neurons in dorsal root ganglia."
      explanation: Defines the sensory neuronopathy as degeneration of dorsal root ganglion neurons.
  - target: Areflexia
    description: Loss of the afferent limb of the monosynaptic stretch reflex abolishes tendon reflexes.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:41964406
      reference_title: "Homozygous RFC1 AAGGG Repeat Expansions Are Common in Idiopathic Peripheral Neuropathy."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "Biallelic intronic AAGGG repeat expansions in RFC1 cause cerebellar ataxia with neuropathy and vestibular areflexia syndrome and may also contribute to isolated sensory neuropathy."
      explanation: >-
        Supports the sensory-neuropathy phenotype; the specific reflex-arc
        mechanism is inferred, hence PARTIAL.
  - target: Multisensory Balance Failure
    description: Proprioceptive loss removes one of the three balance-control channels.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33492056
      reference_title: "The Pathology of the Vestibular System in CANVAS."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "characterized by progressive imbalance due to a combination of cerebellar, somatosensory, and selective vestibular impairment with normal hearing"
      explanation: States that imbalance arises from the combination of the three deficits.
- name: Cranial Sensory Ganglionopathy
  biological_scale: CELLULAR
  description: >-
    Severe loss of vestibular ganglion neurons with atrophy of the vestibular
    nerves, while vestibular hair cells and vestibular nuclei are preserved — the
    lesion is the first-order neuron, not the end organ or the central relay. The
    trigeminal and geniculate ganglia degenerate too, whereas the auditory ganglion
    is relatively spared, which is the anatomical basis for the clinically
    characteristic combination of destroyed vestibular function with normal hearing.
  cell_types:
  - preferred_term: vestibular ganglion neuron
    term:
      id: CL:0000101
      label: sensory neuron
    modifier: DECREASED
  evidence:
  - reference: PMID:33492056
    reference_title: "The Pathology of the Vestibular System in CANVAS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All five temporal bones showed severe loss of vestibular ganglion cells (cell counts 3-16% of normal), and atrophy of the vestibular nerves, whereas vestibular receptor hair cells and the vestibular nuclei were preserved."
    explanation: Localizes the vestibular lesion to the ganglion with sparing of hair cells and nuclei.
  - reference: PMID:33492056
    reference_title: "The Pathology of the Vestibular System in CANVAS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In contrast, auditory receptor hair cells, the auditory ganglia (cell counts 51-100% of normal), and the auditory nerves were relatively preserved."
    explanation: Documents auditory sparing, explaining preserved hearing.
  downstream:
  - target: Vestibular areflexia
    description: Loss of vestibular first-order neurons abolishes the vestibulo-ocular reflex bilaterally.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33492056
      reference_title: "The Pathology of the Vestibular System in CANVAS."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "To describe the site of lesion responsible for the severe, bilateral, symmetrical, selective loss of vestibular function"
      explanation: Identifies the ganglionic lesion as the site responsible for vestibular loss.
  - target: Oscillopsia
    description: >-
      Failure of the vestibulo-ocular reflex prevents gaze stabilization during head
      motion, producing apparent movement of the visual scene.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Loss of the vestibulo-ocular reflex and failure of gaze stabilization during head movement
    evidence:
    - reference: PMID:33492056
      reference_title: "The Pathology of the Vestibular System in CANVAS."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "severe, bilateral, symmetrical, selective loss of vestibular function in Cerebellar Ataxia with Neuronopathy and Vestibular Areflexia Syndrome (CANVAS)"
      explanation: >-
        Supports bilateral vestibular loss; oscillopsia as its perceptual
        consequence is inferred, hence PARTIAL.
  - target: Multisensory Balance Failure
    description: Vestibular loss removes a second balance-control channel.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33492056
      reference_title: "The Pathology of the Vestibular System in CANVAS."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "progressive imbalance due to a combination of cerebellar, somatosensory, and selective vestibular impairment"
      explanation: Names vestibular impairment as one of the three contributors to imbalance.
- name: Autonomic Ganglion Involvement
  biological_scale: CELLULAR
  description: >-
    Dysautonomia — orthostatic hypotension, erectile dysfunction, and bowel and
    bladder disturbance — is one of the five recognised components of the RFC1
    spectrum. It is clinically important beyond its own morbidity because it is a
    principal reason CANVAS is mistaken for multiple system atrophy, from which it
    is distinguished by its far slower course. Whether the lesion sits in the
    autonomic ganglia themselves is inferred from the demonstrated sensory
    ganglionopathy rather than directly shown, and is recorded here as an inference.
  evidence:
  - reference: PMID:33237689
    reference_title: "RFC1 CANVAS / Spectrum Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "(4) autonomic dysfunction; and (5) cough"
    explanation: GeneReviews lists autonomic dysfunction as a component of the RFC1 spectrum.
  downstream:
  - target: Autonomic dysfunction
    description: Autonomic involvement manifests as orthostatic, sexual, bowel, and bladder dysfunction.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33237689
      reference_title: "RFC1 CANVAS / Spectrum Disorder."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "(4) autonomic dysfunction; and (5) cough"
      explanation: GeneReviews names autonomic dysfunction directly.
- name: Vagal Afferent Cough Reflex Hypersensitivity
  biological_scale: CELLULAR
  description: >-
    Chronic dry cough is attributed to sensory neuronopathy affecting vagal and
    laryngeal afferents, producing a neurogenic cough with heightened cough reflex
    sensitivity. Because this arm involves a different sensory ganglion population
    from the balance pathways, it can present in isolation and typically precedes
    the neurological features by years to decades.
  evidence:
  - reference: PMID:39811557
    reference_title: "Repeat expansions in RFC1 gene in refractory chronic cough."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "RFC1++ participants had heightened cough reflex sensitivity to capsaicin, similar to previous CANVAS and RCC studies."
    explanation: Demonstrates cough reflex hypersensitivity in biallelic RFC1 expansion carriers.
  downstream:
  - target: Chronic cough
    description: >-
      Cough reflex hypersensitivity manifests as a chronic dry cough that is
      typically refractory to conventional antitussive management.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39811557
      reference_title: "Repeat expansions in RFC1 gene in refractory chronic cough."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Biallelic RFC1 repeat expansions (RFC1++) were present in 8% of RCC patients."
      explanation: Links biallelic RFC1 expansion to refractory chronic cough.
- name: Cerebellar Purkinje Cell Loss
  biological_scale: CELLULAR
  conforms_to: "cerebellar_purkinje_degeneration#Purkinje Neuron Degeneration"
  description: >-
    Degeneration of cerebellar Purkinje neurons, predominantly in the vermis, which
    is the anatomical correlate of the vermian atrophy seen on MRI and of the
    cerebellar component of the ataxia.
  cell_types:
  - preferred_term: Purkinje cell
    term:
      id: CL:0000121
      label: Purkinje cell
    modifier: DECREASED
  evidence:
  - reference: PMID:24682971
    reference_title: "Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cerebellar pathology showed loss of Purkinje cells, predominantly in the vermis."
    explanation: Post-mortem evidence of vermis-predominant Purkinje cell loss.
  downstream:
  - target: Cerebellar atrophy
    description: Purkinje neuron loss produces the vermis-predominant cerebellar atrophy seen on imaging.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24682971
      reference_title: "Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cerebellar pathology showed loss of Purkinje cells, predominantly in the vermis."
      explanation: Vermis-predominant Purkinje loss is the substrate of cerebellar atrophy.
  - target: Progressive cerebellar ataxia
    description: Loss of cerebellar cortical output produces gait and limb ataxia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Loss of Purkinje cell inhibitory output to the deep cerebellar nuclei
    evidence:
    - reference: PMID:37301658
      reference_title: "CANVAS, a sensory neuronopathy to look for in ataxia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "CANVAS is a clinical entity associating cerebellar ataxia, sensory neuronopathy and vestibular areflexia due to biallelic expansions in RFC1."
      explanation: Establishes cerebellar ataxia as a defining component.
  - target: Dysphagia
    description: >-
      Bulbar and cerebellar incoordination impairs swallowing, and the resulting
      aspiration risk is an explicit surveillance target in the GeneReviews
      management guidance.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33237689
      reference_title: "RFC1 CANVAS / Spectrum Disorder."
      supports: PARTIAL
      evidence_source: OTHER
      snippet: "aspiration risk and feeding methods"
      explanation: >-
        GeneReviews places aspiration risk under surveillance, implying clinically
        significant dysphagia; the cerebellar/bulbar attribution is inferred, hence
        PARTIAL.
  - target: Dysarthria
    description: Cerebellar degeneration impairs the coordination of speech musculature.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33237689
      reference_title: "RFC1 CANVAS / Spectrum Disorder."
      supports: PARTIAL
      evidence_source: OTHER
      snippet: "typical cerebellar ataxia, neuropathy, vestibular areflexia syndrome (CANVAS)"
      explanation: >-
        Supports cerebellar involvement; dysarthria as a specific cerebellar output
        is inferred, hence PARTIAL.
  - target: Multisensory Balance Failure
    description: Cerebellar degeneration removes the third balance-control channel.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33492056
      reference_title: "The Pathology of the Vestibular System in CANVAS."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "progressive imbalance due to a combination of cerebellar, somatosensory, and selective vestibular impairment"
      explanation: Names cerebellar impairment as one of the three contributors to imbalance.
- name: Multisensory Balance Failure
  biological_scale: ORGANISM
  description: >-
    The clinically defining feature of CANVAS is that all three systems used to
    stabilise posture and gaze — proprioception, vestibular input, and cerebellar
    processing — fail together. Because each system normally compensates for loss of
    the others, their simultaneous failure produces imbalance disproportionate to
    any single deficit. This triple-deafferentation is why CANVAS causes greater
    disability than an isolated sensory neuronopathy, isolated vestibulopathy, or
    isolated cerebellar degeneration of comparable individual severity.
  evidence:
  - reference: PMID:33492056
    reference_title: "The Pathology of the Vestibular System in CANVAS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "characterized by progressive imbalance due to a combination of cerebellar, somatosensory, and selective vestibular impairment with normal hearing"
    explanation: >-
      States explicitly that the imbalance arises from the combination of the three
      impairments.
  downstream:
  - target: Progressive gait imbalance and falls
    description: >-
      Loss of all three balance channels produces progressive unsteadiness and a
      high falls risk, the dominant source of disability.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33492056
      reference_title: "The Pathology of the Vestibular System in CANVAS."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "an adult-onset recessively-inherited ataxia, characterized by progressive imbalance"
      explanation: Documents progressive imbalance as the clinical consequence.
phenotypes:
- category: Neurological
  name: Progressive cerebellar ataxia
  frequency: FREQUENT
  description: >-
    Progressive gait and limb ataxia from cerebellar degeneration, one of the three
    defining deficits. Present in about two thirds of patients after ten years of
    disease.
  phenotype_term:
    preferred_term: Progressive cerebellar ataxia
    term:
      id: HP:0002073
      label: Progressive cerebellar ataxia
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:37301658
    reference_title: "CANVAS, a sensory neuronopathy to look for in ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CANVAS is a clinical entity associating cerebellar ataxia, sensory neuronopathy and vestibular areflexia due to biallelic expansions in RFC1."
    explanation: Establishes cerebellar ataxia as a defining feature.
  - reference: PMID:33237689
    reference_title: "RFC1 CANVAS / Spectrum Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In a retrospective study of 100 affected individuals after ten years of disease duration, two thirds had clinical features of CANVAS; 16 had a complex sensory ataxia with cerebellar or vestibular involvement; and 15 had a sensory neuropathy as the only clinically detectable manifestation"
    explanation: >-
      Derived count: of 100 individuals, 66 had the full triad and a further 16 had
      cerebellar or vestibular involvement, bounding cerebellar involvement at
      66-82% and placing it in the FREQUENT (30-79%) band, which covers most of
      that interval.
- category: Neurological
  name: Vestibular areflexia
  frequency: FREQUENT
  description: >-
    Bilateral, symmetrical, selective loss of vestibular function with an abnormal
    vestibulo-ocular reflex, in the presence of normal hearing.
  phenotype_term:
    preferred_term: Vestibular areflexia
    term:
      id: HP:0008568
      label: Vestibular areflexia
  evidence:
  - reference: PMID:33492056
    reference_title: "The Pathology of the Vestibular System in CANVAS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "severe, bilateral, symmetrical, selective loss of vestibular function"
    explanation: Documents the bilateral selective vestibular loss.
  - reference: PMID:33237689
    reference_title: "RFC1 CANVAS / Spectrum Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In a retrospective study of 100 affected individuals after ten years of disease duration, two thirds had clinical features of CANVAS; 16 had a complex sensory ataxia with cerebellar or vestibular involvement; and 15 had a sensory neuropathy as the only clinically detectable manifestation"
    explanation: >-
      Derived count: 66 of 100 had the full triad and a further 16 had cerebellar or
      vestibular involvement, bounding vestibular involvement at 66-82% and placing
      it in the FREQUENT (30-79%) band, which covers most of that interval.
- category: Neurological
  name: Sensory ataxia
  description: >-
    Ataxia from proprioceptive deafferentation, distinct in mechanism from the
    cerebellar ataxia and additive with it.
  phenotype_term:
    preferred_term: Sensory ataxia
    term:
      id: HP:0010871
      label: Sensory ataxia
  evidence:
  - reference: PMID:37301658
    reference_title: "CANVAS, a sensory neuronopathy to look for in ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sensory neuronopathies name the degeneration of peripheral sensory neurons in dorsal root ganglia."
    explanation: Defines the sensory neuronopathy underlying sensory ataxia.
- category: Neurological
  name: Impaired proprioception
  description: Loss of position and vibration sense from dorsal root ganglion neuronal loss.
  phenotype_term:
    preferred_term: Impaired proprioception
    term:
      id: HP:0010831
      label: Impaired proprioception
  evidence:
  - reference: PMID:24682971
    reference_title: "Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS."
    explanation: Attributes sensory impairment to the dorsal root ganglionopathy.
- category: Neurological
  name: Sensory neuropathy
  description: >-
    A non-length-dependent sensory neuronopathy with reduced or absent sensory nerve
    action potentials. It may be the only clinically detectable manifestation, and
    motor involvement does not exclude the diagnosis.
  phenotype_term:
    preferred_term: Sensory neuropathy
    term:
      id: HP:0000763
      label: Sensory neuropathy
  evidence:
  - reference: PMID:33237689
    reference_title: "RFC1 CANVAS / Spectrum Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "15 had a sensory neuropathy as the only clinically detectable manifestation"
    explanation: Sensory neuropathy can be the sole manifestation of the spectrum.
  - reference: PMID:41964406
    reference_title: "Homozygous RFC1 AAGGG Repeat Expansions Are Common in Idiopathic Peripheral Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These data indicate that motor nerve involvement should not exclude patients from RFC1 repeat screening."
    explanation: Motor involvement does not exclude RFC1-related disease.
- category: Neurological
  name: Areflexia
  description: Absent tendon reflexes from loss of the afferent limb of the stretch reflex.
  phenotype_term:
    preferred_term: Areflexia
    term:
      id: HP:0001284
      label: Areflexia
  evidence:
  - reference: PMID:24682971
    reference_title: "Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "The likely underlying sensory pathology in CANVAS is loss of neurons from the dorsal root and V, VII, and VIII cranial nerve ganglia"
    explanation: >-
      Supports dorsal root ganglion neuronal loss; areflexia as its reflex-arc
      consequence is inferred, hence PARTIAL.
- category: Neurological
  name: Autonomic dysfunction
  description: >-
    Dysautonomia including orthostatic hypotension, erectile dysfunction, and bowel
    and bladder disturbance. Clinically it is a principal reason CANVAS is
    misdiagnosed as multiple system atrophy.
  phenotype_term:
    preferred_term: Autonomic dysfunction
    term:
      id: HP:0012332
      label: Abnormal autonomic nervous system physiology
  evidence:
  - reference: PMID:33237689
    reference_title: "RFC1 CANVAS / Spectrum Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "(4) autonomic dysfunction; and (5) cough"
    explanation: GeneReviews lists autonomic dysfunction as a component of the RFC1 spectrum.
- category: Gastrointestinal
  name: Dysphagia
  description: >-
    Swallowing difficulty from bulbar and cerebellar incoordination, with associated
    aspiration risk that GeneReviews places under active surveillance.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:33237689
    reference_title: "RFC1 CANVAS / Spectrum Disorder."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "aspiration risk and feeding methods"
    explanation: >-
      GeneReviews surveillance of aspiration risk and feeding implies clinically
      significant dysphagia; the phenotype is inferred from the management text,
      hence PARTIAL.
- category: Respiratory
  name: Chronic cough
  frequency: FREQUENT
  description: >-
    A chronic dry cough, typically refractory to conventional treatment, that
    frequently begins years to decades before neurological onset and is the single
    most useful early diagnostic clue.
  phenotype_term:
    preferred_term: Chronic cough
    term:
      id: HP:0034315
      label: Chronic cough
    temporality: CHRONIC
  evidence:
  - reference: PMID:37301658
    reference_title: "CANVAS, a sensory neuronopathy to look for in ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clinical picture showed that chronic cough was a frequent sign beginning before the onset of other symptoms."
    explanation: >-
      Documents chronic cough preceding the other manifestations, and supplies the
      qualitative frequency term ("a frequent sign") that maps to the FREQUENT
      (30-79%) band under the frequency-evidence SOP.
  - reference: PMID:39811557
    reference_title: "Repeat expansions in RFC1 gene in refractory chronic cough."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Biallelic RFC1 repeat expansions (RFC1++) were present in 8% of RCC patients."
    explanation: Quantifies biallelic RFC1 expansion among refractory chronic cough patients.
- category: Neurological
  name: Oscillopsia
  description: Apparent movement of the visual scene during head motion from vestibulo-ocular reflex failure.
  phenotype_term:
    preferred_term: Oscillopsia
    term:
      id: HP:0034773
      label: Oscillopsia
  evidence:
  - reference: PMID:33492056
    reference_title: "The Pathology of the Vestibular System in CANVAS."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "severe, bilateral, symmetrical, selective loss of vestibular function"
    explanation: >-
      Supports the bilateral vestibular loss that causes oscillopsia; the symptom
      itself is inferred, hence PARTIAL.
- category: Neurological
  name: Dysarthria
  description: Cerebellar dysarthria from degeneration of cerebellar speech-coordination circuits.
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:33237689
    reference_title: "RFC1 CANVAS / Spectrum Disorder."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "typical cerebellar ataxia, neuropathy, vestibular areflexia syndrome (CANVAS)"
    explanation: >-
      Supports the cerebellar syndrome of which dysarthria is a component; the
      specific feature is inferred, hence PARTIAL.
- category: Neurological
  name: Cerebellar atrophy
  description: Vermis-predominant cerebellar atrophy on MRI, corresponding to Purkinje cell loss.
  phenotype_term:
    preferred_term: Cerebellar atrophy
    term:
      id: HP:0001272
      label: Cerebellar atrophy
  evidence:
  - reference: PMID:24682971
    reference_title: "Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cerebellar pathology showed loss of Purkinje cells, predominantly in the vermis."
    explanation: Neuropathological basis of the vermis-predominant atrophy.
- category: Neurological
  name: Progressive gait imbalance and falls
  description: >-
    Progressive unsteadiness from the combined failure of proprioceptive,
    vestibular, and cerebellar balance control; the dominant source of disability.
  phenotype_term:
    preferred_term: Progressive gait unsteadiness with falls
    term:
      id: HP:0002317
      label: Unsteady gait
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:33492056
    reference_title: "The Pathology of the Vestibular System in CANVAS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "an adult-onset recessively-inherited ataxia, characterized by progressive imbalance"
    explanation: Documents progressive imbalance as the clinical course.
histopathology:
- name: Sensory ganglion neuronal loss
  description: >-
    Marked neuronal loss in the dorsal root ganglia with secondary degeneration of
    the posterior column tracts, and severe depletion of vestibular ganglion cells
    (3-16% of normal counts) with preserved vestibular hair cells and nuclei. The
    trigeminal and geniculate ganglia are also affected while the auditory ganglion
    is relatively preserved.
  evidence:
  - reference: PMID:33492056
    reference_title: "The Pathology of the Vestibular System in CANVAS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All five temporal bones showed severe loss of vestibular ganglion cells (cell counts 3-16% of normal), and atrophy of the vestibular nerves, whereas vestibular receptor hair cells and the vestibular nuclei were preserved."
    explanation: Quantitative histopathology of the vestibular ganglionopathy.
  - reference: PMID:24682971
    reference_title: "Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Spinal cord pathology demonstrated a marked dorsal root ganglionopathy with secondary tract degeneration."
    explanation: Spinal histopathology of the dorsal root ganglionopathy.
- name: Cerebellar Purkinje cell depletion
  description: Loss of Purkinje cells with a vermis predominance.
  evidence:
  - reference: PMID:24682971
    reference_title: "Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cerebellar pathology showed loss of Purkinje cells, predominantly in the vermis."
    explanation: Cerebellar histopathology.
diagnosis:
- name: Targeted RFC1 repeat expansion testing
  description: >-
    Molecular diagnosis requires testing specifically targeted to the intronic
    repeat, such as repeat-primed and flanking PCR or long-read sequencing. This is
    the single most important diagnostic point in the disorder: the expansion is
    intronic and absent from the reference genome, so exome sequencing and
    sequence-based gene panels do not detect it, and a negative panel does not
    exclude the diagnosis. Assay design must also account for motif heterogeneity,
    because an assay built only for AAGGG will miss ACAGG and the Maori
    configuration.
  evidence:
  - reference: PMID:33237689
    reference_title: "RFC1 CANVAS / Spectrum Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Note that pathogenic RFC1 AAGGG repeat expansions cannot be detected by sequence-based multigene panels or exome sequencing."
    explanation: Establishes that standard sequencing approaches miss the expansion.
  - reference: PMID:40481300
    reference_title: "Comprehensive Characterisation of the RFC1 Repeat in an Australian Cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We also demonstrate the utility of targeted long-read sequencing in resolving complex alleles."
    explanation: Supports long-read sequencing for resolving complex repeat alleles.
- name: Nerve conduction studies
  description: >-
    Sensory nerve action potentials are reduced or absent in a non-length-dependent
    distribution, consistent with a ganglionopathy rather than a dying-back
    axonopathy.
  evidence:
  - reference: PMID:39811557
    reference_title: "Repeat expansions in RFC1 gene in refractory chronic cough."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "RFC1++ participants had impaired sensory action potentials, and one had cerebellar atrophy."
    explanation: Documents impaired sensory action potentials in biallelic carriers.
- name: Vestibular function testing
  description: >-
    Bilateral vestibular hypofunction is demonstrated by an abnormal vestibulo-ocular
    reflex, with preserved audiometric function — a dissociation that reflects the
    sparing of the auditory ganglion. At the bedside the visually enhanced VOR
    (VVOR) is the most useful manoeuvre, because it tests vestibular, visual, and
    cerebellar contributions to gaze stabilisation together and is therefore
    abnormal in CANVAS when a single-system test might not be. Head-impulse testing
    and oculomotor examination for nystagmus complete the assessment.
  evidence:
  - reference: PMID:33492056
    reference_title: "The Pathology of the Vestibular System in CANVAS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cerebellar, somatosensory, and selective vestibular impairment with normal hearing"
    explanation: Establishes the vestibular-loss-with-normal-hearing dissociation.
prevalence:
- population: Worldwide (birth prevalence of the recessive trait)
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 5.0
  notes: >-
    Estimated birth prevalence of the biallelic (recessive) genotype, derived from
    the observed carrier frequency. This is the population figure; the two records
    below are diagnostic yields in ascertained clinical cohorts and are not
    comparable to it.
  evidence:
  - reference: PMID:30926972
    reference_title: "Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with an estimated prevalence at birth of the recessive trait of approximately 1 in 20,000"
    explanation: Population birth prevalence of the recessive genotype, i.e. 5 per 100,000.
- population: Australian adult-onset ataxia cohort
  measure_type: UNKNOWN
  prevalence_class: COMMON
  notes: >-
    Among individuals presenting with adult-onset ataxia, biallelic pathogenic RFC1
    variants accounted for 34.1% of cases — a diagnostic yield, not a population
    prevalence. RFC1 expansion is among the most common identified genetic causes of
    late-onset ataxia.
  evidence:
  - reference: PMID:40481300
    reference_title: "Comprehensive Characterisation of the RFC1 Repeat in an Australian Cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Biallelic pathogenic RFC1 variants were identified in 34.1% of affected individuals."
    explanation: Diagnostic yield of RFC1 testing in an adult-onset ataxia cohort.
- population: European general population (carrier frequency)
  measure_type: CARRIER_FREQUENCY
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 700.0
  notes: >-
    Heterozygous carrier frequency of the pathogenic AAGGG expansion was estimated
    at 0.7% in Europeans in the original report, and at approximately 1 in 16 in
    Australian controls. This is unusually high for a recessive disorder and
    underlies both pseudodominant inheritance and the likelihood of underdiagnosis.
  evidence:
  - reference: PMID:30926972
    reference_title: "Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "an expansion carrier frequency of 0.7% in Europeans"
    explanation: Original carrier-frequency estimate in Europeans.
- population: US idiopathic peripheral neuropathy cohort
  measure_type: UNKNOWN
  prevalence_class: COMMON
  notes: >-
    Biallelic RFC1 expansions were found in 2.3% of patients with idiopathic
    peripheral neuropathy versus 1 of 778 controls, rising to 6.9% in the pure
    sensory subgroup. This is a diagnostic yield in an ascertained cohort, so no
    rate_per_100000 or numeric population band is asserted — quoting one would
    invite exactly the population-rate reading the UNKNOWN measure_type guards
    against. The population figure is the birth-prevalence record above.
  evidence:
  - reference: PMID:41964406
    reference_title: "Homozygous RFC1 AAGGG Repeat Expansions Are Common in Idiopathic Peripheral Neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Biallelic RFC1 expansions were present in only 1 out of 778 controls but present in 18 out of 788 (2.3%) patients with iPN"
    explanation: Case-control comparison of biallelic expansion frequency in idiopathic neuropathy.
progression:
- phase: Onset
  age_range: After age 35 years
  notes: >-
    Neurological onset begins after age 35. Chronic cough commonly precedes
    neurological onset by years to decades, making it the earliest clue.
  evidence:
  - reference: PMID:33237689
    reference_title: "RFC1 CANVAS / Spectrum Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Onset begins after age 35 years."
    explanation: Establishes the late-onset course.
- phase: Established disease
  age_range: Ten years after onset
  notes: >-
    The full triad may take over a decade to assemble, and a substantial minority
    never develop all three components.
  evidence:
  - reference: PMID:33237689
    reference_title: "RFC1 CANVAS / Spectrum Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "two thirds had clinical features of CANVAS; 16 had a complex sensory ataxia with cerebellar or vestibular involvement; and 15 had a sensory neuropathy as the only clinically detectable manifestation"
    explanation: Documents the partial-phenotype spectrum after ten years of disease.
treatments:
- name: Multidisciplinary Supportive Care
  description: >-
    No disease-modifying therapy exists. Management is supportive and coordinated
    across neurology, physical and occupational therapy, physiatry, and — as needed
    — speech therapy, respiratory therapy, nutrition, and gastroenterology, with the
    goals of maximising function and reducing complications. Surveillance covers
    progression of neurological findings, mobility and self-help skills,
    communication needs, and aspiration risk.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:33237689
    reference_title: "RFC1 CANVAS / Spectrum Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The goals of treatment are to maximize function and reduce complications."
    explanation: GeneReviews management principle.
  - reference: PMID:33237689
    reference_title: "RFC1 CANVAS / Spectrum Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "each affected individual should be managed by a multidisciplinary team of relevant specialists such as neurologists, occupational therapists, physical therapists, physiatrists"
    explanation: Supports the multidisciplinary management model.
- name: Physical and Vestibular Rehabilitation
  description: >-
    Physical and occupational therapy for gait, balance, and falls prevention.
    Rehabilitation is constrained in CANVAS in a way that is mechanistically
    informative: standard vestibular rehabilitation relies on substituting
    proprioceptive and visual cues for lost vestibular input, but proprioception is
    also lost here, which limits the usual compensation strategy.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  evidence:
  - reference: PMID:33237689
    reference_title: "RFC1 CANVAS / Spectrum Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "occupational therapists, physical therapists, physiatrists"
    explanation: GeneReviews identifies rehabilitation specialists in the care team.
- name: Avoidance of Neurotoxic Agents
  description: >-
    A specific and actionable management point: agents toxic to the peripheral
    nerves (neurotoxic chemotherapy, pyridoxine), the cerebellum (phenytoin), or the
    vestibular system (aminoglycosides) should be avoided, as should chronic alcohol
    consumption. Each of these targets a system already compromised in CANVAS, so
    exposure risks compounding an existing deficit.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:33237689
    reference_title: "RFC1 CANVAS / Spectrum Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Medications of known toxicity for peripheral nerves (e.g., neurotoxic chemotherapy agents, pyridoxine), the cerebellum (e.g., phenytoin), or the vestibular system (e.g., aminoglycosides); chronic alcohol consumption."
    explanation: GeneReviews agents/circumstances to avoid.
- name: Genetic Counseling
  description: >-
    Autosomal recessive counseling with a 25% sibling recurrence risk when both
    parents are carriers. Counseling must address pseudodominance, since the high
    carrier frequency means affected individuals can appear in consecutive
    generations and be mistaken for dominant transmission.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:33237689
    reference_title: "RFC1 CANVAS / Spectrum Disorder."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier"
    explanation: Recurrence risks for genetic counseling.
discussions:
- discussion_id: canvas_mechanism_unresolved
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    How does a biallelic intronic repeat expansion cause selective degeneration of
    sensory ganglion and Purkinje neurons when it does not reduce RFC1 expression?
  attaches_to:
  - "pathophysiology#Repeat-Intrinsic Nucleic Acid Structural Toxicity"
  rationale: >-
    This is the central unresolved question of the disorder. The original
    patient-tissue work found RFC1 expression unaffected in peripheral and brain
    tissue, which removes the obvious loss-of-function explanation. In vitro
    structural work shows the pathogenic motif forms G-quadruplexes that stall
    replication, but it is not obvious why a replication-associated mechanism would
    selectively kill post-mitotic neurons, nor why it targets sensory ganglia and
    Purkinje cells specifically while sparing the adjacent auditory ganglion. The
    exquisite selectivity of the cell loss is itself the strongest constraint on any
    candidate mechanism.
  proposed_experiments:
  - experiment_id: canvas_ganglion_resolved_rfc1_expression
    name: Ganglion-resolved RFC1 expression comparison
    description: >-
      Compare RFC1 transcript and protein levels directly in affected dorsal root
      and vestibular ganglion neurons versus the spared auditory ganglion from the
      same donors, to test whether a cell-type-restricted loss of function explains
      the selectivity that bulk-tissue measurement missed.
    decision_criterion: >-
      A reduction confined to affected ganglia would revive a loss-of-function
      model; equal levels across affected and spared ganglia would further favour a
      repeat-intrinsic mechanism.
  - experiment_id: canvas_g4_modulation_sensory_neurons
    name: G-quadruplex modulation in patient-derived sensory neurons
    description: >-
      Test whether G-quadruplex-stabilising or -resolving interventions modify
      neuronal phenotypes in patient-derived sensory neurons.
    decision_criterion: >-
      Phenotype rescue by G4 resolution would support the structural-toxicity
      hypothesis and nominate a druggable target.
  - experiment_id: canvas_replication_independent_toxicity
    name: Replication-independent repeat toxicity assay
    description: >-
      Determine whether the repeat produces R-loops in post-mitotic neurons, which
      would provide a route to toxicity that does not require DNA replication. The
      RNA-foci arm of this question is deliberately excluded: Cortese et al. already
      looked for sense and antisense repeat foci in patient brain and did not find
      them, which narrows the search rather than leaving it open.
    decision_criterion: >-
      Detection of R-loops in non-dividing neurons would resolve the paradox of a
      replication-associated gene causing post-mitotic neuronal death; their absence
      would, together with the published negative foci result, argue against the
      whole class of RNA-mediated toxicity models.
    evidence:
    - reference: PMID:30926972
      reference_title: "Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We did not observe in patient brains the presence of RNA foci of either the sense or antisense repeated unit."
      explanation: >-
        Published negative result for repeat RNA foci in patient brain, which is why
        this experiment is scoped to R-loops only.
  evidence:
  - reference: PMID:30926972
    reference_title: "Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "does not affect RFC1 expression in patient peripheral and brain tissue, suggesting no overt loss of function"
    explanation: Establishes the gap by ruling out the obvious loss-of-function mechanism.
- discussion_id: canvas_ganglionopathy_not_axonopathy
  kind: INTERPRETATION
  status: OPEN
  prompt: >-
    Should the peripheral lesion of CANVAS be modeled as a ganglionopathy rather
    than conforming to the length-dependent peripheral axonal degeneration module?
  attaches_to:
  - "pathophysiology#Dorsal Root Ganglion Sensory Neuronopathy"
  rationale: >-
    The dismech module `peripheral_axonal_degeneration` explicitly models
    length-dependent, distal-to-proximal dying-back degeneration producing a
    glove-and-stocking gradient. CANVAS is mechanistically the opposite: the primary
    event is loss of the sensory neuron cell body in the ganglion, with tract
    degeneration secondary, and the resulting sensory loss is not length-dependent.
    This entry therefore deliberately does not declare conformance to that module,
    even though CANVAS would superficially match on the phenotype of peripheral
    sensory loss. Conformance is declared only to
    `cerebellar_purkinje_degeneration`, where the mechanism genuinely matches. A
    future ganglionopathy/sensory-neuronopathy module would be the correct home for
    this pattern, which is shared with paraneoplastic sensory neuronopathy, Sjogren
    ganglionopathy, and pyridoxine toxicity.
  notes: >-
    Flagged as a candidate new mechanism module rather than forcing a conformance
    that would misrepresent the mechanism.
notes: >-
  Curated from the RFC1 CANVAS / Spectrum Disorder GeneReviews chapter plus primary
  neuropathology, genetics, and structural-biology literature. The deep-research
  report additionally described psammoma bodies and satellite glial cell
  proliferation in affected ganglia, basal ganglia atrophy, and iPSC-neuron findings
  in which phenotypes were rescued by repeat correction but not by RFC1
  re-expression. Those claims were not curated here because they could not be tied
  to a verified quotable abstract at curation time; they are strong candidates for a
  follow-up pass. Motor neuron involvement (fasciculations, mild wasting) and
  parkinsonism are likewise real features of the spectrum but are deliberately not
  curated here: none of the cached CANVAS references states a quotable frequency for
  them, so asserting one would violate the frequency-evidence SOP. The intron 2
  retention arm reported by Cortese et al. is a further mechanism thread deferred to
  its own follow-up, since it warrants a node and edges rather than a note.
📚

References & Deep Research

References

1
PMID:33237689
RFC1 CANVAS / Spectrum Disorder.
No top-level findings curated for this source.

Deep Research

1
Claude Code ▸
CANVAS (Cerebellar Ataxia, Neuropathy, and Vestibular Areflexia Syndrome) / RFC1-Related Disease: Comprehensive Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 33 citations 2026-07-30T20:29:22.540660

CANVAS (Cerebellar Ataxia, Neuropathy, and Vestibular Areflexia Syndrome) / RFC1-Related Disease: Comprehensive Research Report

1. Disease Information

Overview: CANVAS is a late-onset (typically 6th decade), recessively inherited neurodegenerative disorder caused by biallelic intronic pentanucleotide repeat expansions in RFC1 (Replication Factor C subunit 1). The eponymous acronym reflects its three cardinal domains: Cerebellar Ataxia, Neuropathy (sensory neuronopathy), and Vestibular Areflexia Syndrome. Since the genetic discovery in 2019, the disease is now understood to represent one pole of a much broader phenotypic continuum, and many authors now prefer the umbrella term "RFC1 CANVAS/spectrum disorder" or simply "RFC1 disease" (NCBI Bookshelf, GeneReviews, https://www.ncbi.nlm.nih.gov/books/NBK564656/).

Key identifiers: - OMIM (phenotype): #614575 — Cerebellar Ataxia, Neuropathy, and Vestibular Areflexia Syndrome; CANVAS - OMIM (gene): 102579 — Replication Factor C, Subunit 1; RFC1 - MONDO: MONDO:0044720 - Orphanet: ORPHA:504476 - SNOMED CT:* 1236804009 - (GARD/NIH also lists it as "Cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome," https://rarediseases.info.nih.gov/diseases/17937/)

Synonyms/alternative names: CANVAS syndrome; RFC1-related ataxia; RFC1 CANVAS/spectrum disorder; RFC1 disease; sensory ataxia with bilateral vestibulopathy and cough. Some limited-phenotype presentations are described in the literature as "CANVAS-minus" (isolated sensory neuronopathy, isolated bilateral vestibulopathy, ataxia with chronic cough, ataxia-neuropathy without vestibular loss).

Evidence base: Information is derived predominantly from aggregated disease-level clinical cohorts (retrospective and prospective multicenter case series, e.g., the 100-patient GeneReviews-cited cohort, the ARCA registry natural history study), rather than single-patient case reports, supplemented by molecular/genetic population-frequency data (gnomAD-style control cohorts) and increasingly by iPSC-neuron and animal-model mechanistic studies.

2. Etiology

Primary cause: Biallelic (homozygous or compound heterozygous), non-reference intronic pentanucleotide repeat expansions in intron 2 of RFC1, most commonly the motif (AAGGG)n replacing the reference (AAAAG)11 allele. This was independently discovered by two groups in 2019: - Cortese A, et al. "Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia." Nat Genet. 2019;51(4):649-658. - Rafehi H, et al. "Bioinformatics-Based Identification of Expanded Repeats: A Non-reference Intronic Pentanucleotide Repeat in RFC1 Causes CANVAS." Am J Hum Genet. 2019;105(1):151-165. PMID: 31178126.

Genetic risk factors: - Biallelic pathogenic repeat configurations at the RFC1 intron 2 locus (see Section 4 for full motif table). - High population carrier frequency of the pathogenic (AAGGG)exp allele creates risk of pseudodominance — apparent vertical transmission across generations in the absence of consanguinity, due to a carrier partner marrying into the family (Cerebellum, 2024, "Pseudodominance in RFC1-Spectrum Disorder," https://link.springer.com/article/10.1007/s12311-024-01735-5). - Population/ethnicity-specific founder configurations (see Section 9).

Environmental risk factors: No environmental/infectious/toxic causal factor is established. However, several agents are reported to exacerbate or unmask the underlying vulnerability rather than cause it: - Neurotoxic chemotherapy agents and pyridoxine (peripheral nerve toxicity) - Phenytoin (cerebellar toxicity) - Aminoglycosides (vestibulotoxicity) - Chronic alcohol use (GeneReviews management section explicitly lists these as agents/circumstances to avoid because they may worsen the phenotype.)

Age/sex: Onset is typically in mid-to-late adulthood (mean ~52 years, range 19–76); no strong sex skew has been consistently reported across cohorts.

Protective factors: None established. Heterozygous carriers of a single pathogenic expansion are, to date, uniformly reported as asymptomatic — i.e., monoallelic carriage itself functions as implicitly "protective" relative to the biallelic state, but no specific protective allele or modifier variant has been validated.

Gene-environment interaction: Not established as a primary disease mechanism; the described environmental "risk factors" act at the level of symptomatic exacerbation of an already-genetically-determined neurodegenerative process (multi-hit model: genetically vulnerable dorsal root ganglion/vestibular ganglion/Purkinje neurons made symptomatic sooner by additional neurotoxic insults).

3. Phenotypes

The clinical picture is a multisystem, spatiotemporally evolving ganglionopathy/cerebellopathy. Using GeneReviews-cited retrospective cohort data (n=100) and additional cohort studies:

Phenotype Frequency Onset/Course Suggested HPO term
Sensory neuropathy/neuronopathy (non-length-dependent, DRG) 100% Often earliest manifestation; progressive HP:0003474 (Peripheral axonal neuropathy) / HP:0007141 (Axonal loss); consider HP:0012394 (sensory neuronopathy context)
Bilateral vestibular areflexia/hypofunction 69% overall (93% of those formally tested) Mid-course; produces oscillopsia HP:0007751 (Bilateral sensorineural hearing impairment - N/A) → better: HP:0025406 (Vestibular dysfunction)
Chronic dry/spasmodic cough 64–97% (higher in some cohorts) Can precede neurologic onset by years-to-decades, sometimes starting in the 2nd–3rd decade HP:0031246 (Chronic cough)
Full CANVAS triad (cerebellar + sensory + vestibular) ~63% (up to two-thirds); full triad may take >10 yrs to manifest Progressive, sequential —
Cerebellar syndrome (gait/limb ataxia, dysarthria, oculomotor signs) 63% Progressive, later-appearing element HP:0001251 (Ataxia); HP:0001260 (Dysarthria); HP:0000639 (Nystagmus); HP:0000751 (Gaze-evoked nystagmus); HP:0007766 (Downbeat nystagmus)
Oscillopsia ~33% Related to bilateral VOR failure HP:0025430-type visual disturbance (no exact dedicated HPO term; often coded under nystagmus/vestibular categories)
Dysautonomia (orthostatic hypotension, erectile dysfunction, constipation, urinary dysfunction, sweating changes) 32–50% Usually mild, rarely disabling (contrasts with MSA) HP:0001278 (Orthostatic hypotension); HP:0000021 (Erectile dysfunction); HP:0002019 (Constipation)
Dysphagia Later-stage Progressive HP:0002015 (Dysphagia)
Motor neuron involvement (fasciculations, mild weakness/wasting) ~55% in some cohorts (motor-neuron-focused study) Can mimic ALS/MND presentations HP:0002380 (Fasciculations); HP:0007083 (motor neuron degeneration context)
Parkinsonism ~10% Overlaps with/mimics atypical parkinsonism, MSA-C HP:0001300 (Parkinsonism)
Truncal/appendicular ataxia, saccadic dysmetria Core cerebellar sign Progressive HP:0002078 (Truncal ataxia); HP:0001305 (Dysmetria)

Quality of life impact: Progressive gait imbalance (worse in darkness, due to combined sensory + vestibular + cerebellar deafferentation) is typically the presenting and most disabling complaint. Natural history data (GeneReviews) indicate: ~50% require an assistive mobility device (cane) by 10 years from onset, and ~25% become wheelchair-dependent by ~15 years; life expectancy is not reduced. Chronic cough itself can be socially disabling and diagnostically misleading (frequently treated for years as idiopathic/refractory chronic cough before neurologic diagnosis) (European Respiratory Society, "CANVAS: a neurogenic cough prototype," https://publications.ersnet.org/content/erjor/10/4/00024-2024).

Diagnostic yield caveat: Even in cohorts selected for the "full" CANVAS phenotype, biallelic RFC1 expansions are found in 82–97% (i.e., some phenocopies without RFC1 expansion exist); in broader "late-onset ataxia" cohorts unselected for the full triad, the yield drops to 14–22% (GeneReviews, https://www.ncbi.nlm.nih.gov/books/NBK564656/).

4. Genetic/Molecular Information

Causal gene: RFC1 (chromosome 4p14; encodes the large subunit of Replication Factor C, the clamp-loader complex for PCNA). OMIM gene: *102579.

Locus/repeat details — normal vs. pathogenic motifs (per GeneReviews and Currie et al., Brain 2023, "Normal and pathogenic variation of RFC1 repeat expansions: implications for clinical diagnosis," https://academic.oup.com/brain/article/146/12/5060/7224416):

Allele class Motif / structure Repeat size Population frequency Pathogenicity
Reference/common normal (AAAAG)11 11 ~0.75 Benign
Normal, expanded but non-pathogenic (AAAAG)12–200 12–200 ~0.13 Benign
Normal, expanded but non-pathogenic (AAAGG)40–1000 40–1000 ~0.08 Benign
Non-pathogenic (heterozygous, found in patients and controls) AAGAG, AGAGG, interrupted AAAAG variable — Benign
Pathogenic (most common) (AAGGG)exp ~400 to >2000 (max reported 2750) allele frequency 0.01–0.04 Fully penetrant when biallelic
Pathogenic (Asia-Pacific/Japanese) (ACAGG)exp ~1000 rare; carrier freq ~0.26% South Asia, ~0% Europe Pathogenic, common in East Asians
Pathogenic (Māori/Cook Islands founder) (AAAGG)10–25(AAGGG)exp(AAAGG)4–6 990–1940 Founder population-specific Pathogenic (Beecroft et al., Brain 2020;143(9):2673-2680)
Other reported pathogenic motifs AGGGC, AAGGC (South Asian family) variable rare Pathogenic in trans with AAGGG or homozygous

The repeat sits within an AluSx3 transposable-element-derived poly(A) tract in intron 2 — i.e., the expansion co-opts a retrotransposon-derived sequence, and the pathogenic (AAGGG)n motif is on the antisense strand relative to the reference (AAAAG)n.

Variant classification/type: Non-coding (intronic) short tandem repeat/microsatellite expansion — a repeat-expansion disorder mechanistically analogous to other STR diseases (e.g., Friedreich ataxia GAA, myotonic dystrophy CTG), but recessive rather than the more typical dominant repeat-expansion pattern. Rare truncating point variants/small indels in RFC1 have also been reported in trans with an expanded allele or, less commonly, biallelically, broadening the allelic spectrum (Neurology, "Truncating Variants in RFC1 in CANVAS," PMC9931080, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931080/).

Allele frequency in population databases: Carrier (heterozygous) frequency of pathogenic AAGGG expansion estimated at 0.7–6.8% depending on population/method, with more conservative recent estimates around 0.2% (2/1000) in Caucasian cohorts once biallelic segregation was more strictly required; ~2.24% in a Chinese Han population. Predicted homozygous/biallelic population frequency ranges from ~1/625 to ~1/712 in earlier estimates (making RFC1 disease one of the most common causes of inherited ataxia), though the more conservative later estimate implies a substantially lower biallelic frequency (GeneReviews; ResearchGate Māori founder study; Neurology Genetics prevalence study, https://www.neurology.org/doi/10.1212/NXG.0000000000000440).

Somatic vs. germline: Germline only; no somatic mosaicism or cancer association reported.

Functional consequence / mechanism (loss-of-function debate): Counter-intuitively for a recessive disease, "preliminary studies have not shown reduced expression or overt loss of function of RFC1 protein" in early work (GeneReviews). More recent mechanistic studies refine this: - The pathogenic (AAGGG)n repeat (DNA and transcribed RNA) forms stable parallel G-quadruplex (G4) structures (and can also form triplex structures), which stall DNA replication forks, reduce RFC1 transcript/gene expression in a tissue-specific manner, and increase cellular sensitivity to DNA damage (PMC10563062; PMC10954463; 2025 bioRxiv "CANVAS causing AAGGG repeat expansions cause tissue-specific reduction in RFC1 expression and increase sensitivity to DNA damage," https://www.biorxiv.org/content/10.1101/2025.11.18.688292). - A 2024 human iPSC-neuron (iNeuron) study (Science Advances, https://www.science.org/doi/10.1126/sciadv.adn2321; PMC11373605) found that CRISPR deletion of a single expanded (AAGGG) allele rescues synaptic/developmental deficits in patient neurons, but simple restoration of RFC1 protein does NOT rescue the phenotype — arguing for a repeat-dependent but RFC1-protein-independent ("RFC1-independent") toxic mechanism, i.e., a repeat-RNA or R-loop/G4-mediated gain-of-toxic-function superimposed on a partial expression loss, rather than a pure loss-of-function model. - Structural work on RFC1 as part of the CTF18-RFC alternative clamp loader (cryo-EM, 2024–2025, eLife/PNAS) clarifies normal RFC1 biology (PCNA loading, replication/repair fidelity) but is not itself CANVAS-specific.

Modifier genes: No clinically validated modifier genes; "no clinically relevant genotype-phenotype correlations have been identified" per GeneReviews, though larger repeat size has been loosely associated with earlier age of onset in some series.

Epigenetics: Not a major established mechanism for CANVAS specifically (contrast with e.g. Fragile X, where CGG expansion drives promoter methylation/silencing); the dominant proposed nucleic-acid mechanism is G-quadruplex/secondary-structure formation rather than DNA methylation-mediated silencing, though tissue-specific transcript reduction is documented.

Chromosomal abnormalities: None; this is a single-locus repeat expansion, not a copy-number/structural chromosomal disorder.

Suggested ontology terms: Gene: HGNC RFC1 (hgnc:9969 approx. — verify via HGNC before use); process: GO:0006281 (DNA repair), GO:0006260 (DNA replication), GO:0032201 (telomere maintenance — related clamp-loader biology), GO:0051973 (positive regulation of telomerase activity — tangential).

5. Environmental Information

  • Environmental factors: None established as causal. As above, certain iatrogenic exposures (neurotoxic chemotherapeutics, pyridoxine excess, phenytoin, aminoglycosides) and chronic alcohol use are documented as aggravating/unmasking factors rather than causal ones.
  • Lifestyle factors: No specific dietary, occupational, or lifestyle causal association reported in the literature reviewed.
  • Infectious agents: None implicated.

6. Mechanism / Pathophysiology

Causal chain (proposed, still partially unresolved):

  1. Trigger: Biallelic intronic (AAGGG)n (or other pathogenic-motif) expansion in RFC1 intron 2, embedded in an AluSx3-derived poly(A) tract.
  2. Molecular consequence: Repeat DNA/RNA folds into G-quadruplex (and triplex) secondary structures → replication fork stalling, tissue-specific reduction of RFC1 transcript, and (per newer iNeuron data) additional RFC1-protein-independent toxic mechanisms affecting neuronal development and synaptic connectivity. Increased sensitivity to DNA damage has also been demonstrated in cellular/Drosophila models.
  3. Cellular process: Selective, non-length-dependent degeneration of specific neuronal populations with high metabolic/genomic-integrity demands: dorsal root ganglion (DRG) sensory neurons, vestibular ganglion neurons, and cranial nerve ganglia V (trigeminal) and VII (facial), plus cerebellar Purkinje cells and (in a subset) motor neurons.
  4. Tissue-level pathology: Post-mortem/pathology studies show ganglionic and nerve-root atrophy with neuronal cell loss replaced by psammoma bodies and satellite (glial) cell proliferation in the DRG/cranial ganglia (a "ganglionopathy"/sensory neuronopathy pattern rather than a classic dying-back axonopathy), plus cerebellar and basal ganglia atrophy with diffuse Purkinje cell loss.
  5. Systemic/clinical output: Progressive sensory ataxia (proprioceptive loss) + bilateral vestibular failure (loss of VOR, oscillopsia) + cerebellar dysfunction (gait/limb ataxia, dysarthria, oculomotor abnormalities) — a triple-deafferentation syndrome that compounds imbalance beyond any single system's contribution. Chronic cough is hypothesized to reflect a similar sensory neuronopathy affecting vagal/laryngeal afferents (a "neurogenic cough" mechanism), often the earliest and longest-preceding symptom.

Molecular pathways: DNA replication/repair pathway (RFC1 as the large subunit of the RFC clamp-loader complex, loading PCNA onto DNA to enable processive DNA polymerase activity — canonical role, GO:0006260, GO:0006281); no classical signaling cascade (Wnt/MAPK/mTOR/PI3K-AKT) has been specifically implicated as primary driver — the mechanism is nucleic-acid structural/genome-integrity based rather than a signal-transduction defect.

Cellular processes: Impaired DNA damage response/replication stress in affected neurons; selective neuronal vulnerability of post-mitotic ganglionic neurons (an interesting paradox for a "replication" gene, suggesting a replication-independent, transcription-coupled or R-loop-related toxicity in non-dividing cells); neurodevelopmental impact demonstrated in zebrafish (impaired granule and Purkinje cell progenitor expansion/differentiation) suggesting RFC1 also has a role in normal neurodevelopmental proliferation, distinct from its adult neurodegenerative role.

Protein dysfunction: Not a classical misfolding/aggregation disease (unlike polyQ repeat disorders) — mechanism centers on the repeat DNA/RNA nucleic acid structure itself (G-quadruplex, R-loop potential) rather than an aberrant RFC1 protein conformer; early studies found preserved RFC1 protein levels overall, though newer tissue-specific transcript-reduction data complicates this.

Immune system involvement: Not a primary autoimmune mechanism; however, satellite glial cell proliferation in ganglia may represent a secondary neuroinflammatory/reactive response to neuronal loss. Note also (separately) that RFC1 expansions have been found at increased frequency in some cohorts of "immune-mediated neuropathy" patients (Scientific Reports 2023, https://www.nature.com/articles/s41598-023-45011-8), raising the possibility of diagnostic overlap/mimicry rather than a shared immune mechanism.

Tissue damage mechanisms: Selective ganglionic/Purkinje neuronal loss (a form of programmed neurodegeneration linked to genomic instability/replication stress) rather than classical oxidative-stress/ischemia/fibrosis mechanisms.

Advanced/omics findings: - Single-cell/model organism: Zebrafish rfc1 loss-of-function model (CRISPR/Cas9) shows a developmental role for rfc1 in expansion/differentiation of cerebellar granule and Purkinje neuronal progenitor pools (Nat Commun 2025, https://www.nature.com/articles/s41467-025-60775-5; PMC12217872). - iPSC-neuron transcriptomic/functional profiling: CANVAS patient-derived iNeurons show synaptic connectivity and neurodevelopmental gene-expression deficits rescued by CRISPR correction of the repeat but not by RFC1 re-expression (Science Advances 2024). - Structural biology: Cryo-EM structures of RFC1-containing clamp loader complexes (2024–2025) clarify normal PCNA-loading biology, providing a structural backdrop, though not disease-specific. - G-quadruplex structural studies: NMR/biophysical work (PMC10563062, PMC10954463) directly demonstrates that pathogenic AAGGG (but not benign AAAAG) repeats form G4/triplex structures that stall replication and dysregulate gene expression — proposed as a druggable structural target (small-molecule G4 ligands, helicases).

Suggested GO terms: GO:0006260 (DNA replication), GO:0006281 (DNA repair), GO:0000731 (DNA synthesis involved in DNA repair), GO:0051983 (regulation of chromosome segregation - tangential), GO:0002087 (regulation of respiratory gaseous exchange by nervous system control of breathing — for cough mechanism, speculative). Suggested CL terms: CL:0000540 (neuron), CL:0000617 (GABAergic neuron - Purkinje cell subtype context), CL:1001580 (Purkinje cell, if available in CL) — verify via OAK; CL:0000561 (amacrine cell — N/A); sensory ganglion neuron terms should be verified (dorsal root ganglion sensory neuron). Suggested UBERON terms: UBERON:0002037 (cerebellum), UBERON:0000044 (dorsal root ganglion), UBERON:0001846 (vestibular ganglion — verify exact ID), UBERON:0001651 (trigeminal ganglion), UBERON:0001654 (facial nerve/geniculate ganglion — verify).

7. Anatomical Structures Affected

Organ level: - Primary: Cerebellum (vermis, crus I especially), peripheral sensory nervous system (dorsal root ganglia), vestibular end-organs/vestibular ganglion (bilateral), cranial nerve ganglia V and VII. - Secondary: Spinal cord (posterior column degeneration visible on MRI as T2 hyperintensity, with cord atrophy), basal ganglia (atrophy reported at autopsy, correlating with parkinsonism in a subset), lower motor neurons (subset with motor neuron involvement/fasciculations), autonomic nervous system (mild). - Body systems: Nervous system (central + peripheral + autonomic); secondarily respiratory system (chronic cough — likely neurogenic/vagal afferent rather than primary pulmonary pathology); gastrointestinal system (dysphagia, constipation); genitourinary system (erectile dysfunction, bladder dysfunction).

Tissue/cell level: Neuronal loss in dorsal root ganglia and cranial sensory ganglia with replacement by psammoma bodies and satellite glial cell proliferation; diffuse cerebellar Purkinje cell loss; cerebellar granule cell layer involvement (per zebrafish developmental model).

Subcellular level: Nuclear/genomic — the core molecular lesion is an intronic DNA repeat forming G-quadruplex secondary structure, implicating nuclear DNA replication/repair machinery (GO Cellular Component: nucleus, replication fork) rather than a specific organelle like mitochondria or lysosome.

Localization: Bilateral and symmetric in essentially all core features (bilateral vestibular areflexia by definition, bilateral/symmetric sensory neuropathy, cerebellar vermian atrophy) — no lateralization reported, consistent with a systemic/genetic rather than focal-structural mechanism.

8. Temporal Development

Onset: Adult/late-onset disease. Mean age of neurological symptom onset ~52 years (range 19–76). Chronic cough, when present, frequently precedes neurological onset by years to decades (onset sometimes in the 2nd–3rd decade of life). Onset pattern is insidious/chronic, not acute or subacute.

Progression: Slowly progressive, with a well-documented spatiotemporal pattern: early involvement of sensory (DRG) neurons, followed years later by vestibular dysfunction, followed by cerebellar dysfunction — full triad may take over a decade to manifest, and only ~two-thirds of patients ever develop all three domains. Disease course is chronic and lifelong (non-remitting), without a defined staging system (unlike cancer staging); natural history/longitudinal imaging studies are ongoing (PubMed 40908706, "Longitudinal Evaluation of Ataxia and Brain Structural Changes in RFC1-Related Disorder").

Progression rate: Notably slower than its key mimic, multiple system atrophy (MSA) — mean survival from onset to death in MSA is ~9.3 years, whereas RFC1 CANVAS/spectrum disorder progresses very slowly and does not appear to shorten life expectancy.

Patterns: No spontaneous remission described. No clearly defined "critical period" for intervention, given the current absence of disease-modifying therapy; the main "window" emphasized in the literature is for early diagnostic recognition (e.g., of isolated chronic cough or bilateral vestibulopathy) to shorten the diagnostic odyssey.

9. Inheritance and Population

Epidemiology: - RFC1-associated repeat expansions are one of the most common identified genetic causes of adult-onset/late-onset ataxia, found in 14–22% of unselected late-onset ataxia cohorts and up to 82–97% of cohorts selected for the full CANVAS phenotype. - Predicted biallelic (disease) population frequency estimates range widely: ~1/625–1/712 (early estimates) down to more conservative later estimates (~2/1000 carrier frequency implying a lower biallelic frequency) in Caucasian populations — reflecting evolving methodology (Southern blot/long-read vs. PCR-only screening) (Neurology Genetics, https://www.neurology.org/doi/10.1212/NXG.0000000000000440). - More than 200 individuals (simplex or familial autosomal recessive pattern) had been reported with biallelic AAGGG expansions as of the GeneReviews review.

Inheritance pattern: Autosomal recessive. Because carrier frequency of the pathogenic allele is unusually high for a recessive disease, pseudodominance (apparent multi-generational transmission mimicking autosomal dominant inheritance) is well documented and should not be mistaken for AD inheritance.

Penetrance: Full penetrance reported for biallelic (AAGGG)exp/(AAGGG)exp and compound heterozygous pathogenic genotypes (age-dependent — the disease is late-onset, so "full penetrance" is realized only with sufficient lifespan/observation).

Expressivity: Variable — phenotypic spectrum ranges from full CANVAS triad to isolated/limited system involvement (pure sensory neuronopathy, isolated bilateral vestibulopathy, isolated cough), with no established genotype-phenotype correlation to explain this variability (repeat size shows only a loose association with age of onset).

Genetic anticipation: Not a feature of this disorder (in contrast to unstable dominant repeat-expansion diseases like Huntington disease or myotonic dystrophy) — consistent with a recessive, non-anticipating repeat disorder.

Germline mosaicism: Not specifically reported/characterized in the literature reviewed.

Founder effects: Multiple population-specific founder configurations documented: - A distinct (AAAGG)10–25(AAGGG)exp(AAAGG)4–6 configuration is a founder allele in New Zealand Māori and Cook Island populations (Beecroft et al., Brain 2020;143(9):2673-2680, ResearchGate summary: "A Maori-Specific RFC1 pathogenic repeat configuration in CANVAS, likely due to a founder allele"). - The (ACAGG)exp motif is common in East Asian populations (identified in Asia-Pacific and Japanese CANVAS families), essentially absent in European cohorts (carrier frequency 0% Europe, 0.03% Africa, 0.26% South Asia). - The common (AAGGG)exp allele is the predominant pathogenic configuration in European/Caucasian populations.

Consanguinity: Not a major driver given the relatively high population carrier frequency of pathogenic alleles (unlike most rare AR diseases where consanguinity is the dominant risk factor); however, consanguinity would still increase biallelic risk in any given family.

Carrier frequency: Heterozygous carrier frequency 0.7–4% in populations of Northern European origin; ~2.24% in Chinese Han; ranges up to 6.5–6.8% reported in some individual control cohorts, with more conservative pooled estimates around 0.2–2/1000 for confirmed biallelic-pathogenic carriers in later, more rigorously validated cohorts.

Population demographics: No strong sex-ratio skew reported in the literature surveyed. Geographic/ethnic variation is substantial and motif-specific (see founder effects above) — curators should note that a given population's dominant pathogenic motif differs (AAGGG in Europeans, ACAGG in East Asians, the compound AAAGG/AAGGG/AAAGG configuration in Māori/Cook Islanders), which has direct implications for assay design (repeat-primed PCR designed only for AAGGG will miss ACAGG or Māori-configuration alleles).

10. Diagnostics

Clinical suspicion: Onset after age 35 (though can be younger) with one or more of: sensory neuropathy/neuronopathy, bilateral vestibular dysfunction, cerebellar dysfunction, chronic cough, or dysautonomia. No formal consensus diagnostic criteria have been established (per GeneReviews).

Electrophysiology: - Nerve conduction studies: reduced/absent sensory nerve action potentials (SNAPs) with normal motor conduction studies — the electrophysiological signature of a sensory neuronopathy/ganglionopathy (non-length-dependent). - Abnormal blink reflex; H-reflex often preserved. - Nerve ultrasound: reduced nerve cross-sectional area (a discriminating feature vs. inflammatory neuropathies), now formally studied as a predictive tool alongside cough and neuronopathy pattern (Brain Communications 2025, "Nerve ultrasound, neuronopathy and cough predict sensory neuropathy patients with RFC1 expansions," PMC12662233).

Vestibular testing: Bilaterally abnormal video head impulse test (vHIT); reduced/absent caloric responses; abnormal VOR gain — confirms bilateral vestibular areflexia/hypofunction.

Imaging: - Brain MRI: cerebellar atrophy, particularly vermian and crus I atrophy (can be subtle early in disease). - Spine MRI: spinal cord atrophy and T2-weighted posterior-column hyperintensity (dorsal column degeneration signature). - Comprehensive multimodal deep-phenotyping studies integrating electrophysiology + imaging + otoneurological data are an active area of research (PMC12558705).

Pathology/biopsy: Not typically required for diagnosis; when performed (autopsy/rare biopsy series), shows ganglionic/nerve-root atrophy, neuronal loss, psammoma bodies, satellite glial cell proliferation, and diffuse Purkinje cell loss with cerebellar/basal ganglia atrophy.

Genetic testing (central to diagnosis): - Cannot be detected by standard sequence-based multigene panels or exome sequencing — this is a critical practical point, since the pathogenic repeat is intronic and expanded, invisible to short-read exome capture. - Repeat-primed PCR (RP-PCR) and conventional PCR are first-line targeted assays (must specifically target the pathogenic motif(s) — AAGGG, and regionally ACAGG or the Māori configuration as appropriate). - Southern blotting is used for definitive sizing and confirmation of biallelic status. - Long-read sequencing (e.g., Oxford Nanopore, PacBio) is an emerging/gold-standard technology that can resolve repeat motif, size, and complex/compound configurations in one assay, and is increasingly used to reanalyze existing genome sequencing data to improve diagnostic yield (medRxiv 2024, "RFC1 repeat expansion analysis from whole genome sequencing data simplifies screening and increases diagnostic rates"). - Standard short-read genome sequencing can raise suspicion of an expansion (via specialized repeat-expansion-calling algorithms, e.g., ExpansionHunter) but generally requires orthogonal confirmation (RP-PCR/Southern/long-read).

Differential diagnosis (detailed in GeneReviews): - Multiple system atrophy (MSA) — the single most important mimic/misdiagnosis risk, especially the MSA-cerebellar (MSA-C) and parkinsonian subtypes; distinguished by RFC1 disease's slower progression, normal life expectancy, milder dysautonomia, presence of sensory neuronopathy and bilateral vestibular failure, and absence of the "hot cross bun" pontine sign or severe putaminal atrophy on MRI. - Spinocerebellar ataxia type 3 (SCA3/Machado-Joseph disease) — dystonic-rigid extrapyramidal signs, sensorimotor (not pure sensory) neuropathy, ophthalmoplegia. - Friedreich ataxia (late-onset presentations) — typical onset <25 years, cardiomyopathy, diabetes, skeletal deformity, pyramidal signs. - Mitochondrial disorders (NARP, MIDD, Kearns-Sayre, POLG-related) — earlier onset, multisystem involvement, ophthalmoplegia, hearing/vision loss. - RNF170-related disease — sensory ataxia + vestibular areflexia but normal cerebellar function/SNAPs. - Usher syndrome types I/II — vestibular hypofunction plus hearing and visual loss. - Other causes of bilateral vestibular areflexia (aminoglycoside ototoxicity, Ménière disease, bilateral vestibular neuritis, NF2, infectious/inflammatory vestibulopathy). - Idiopathic/immune-mediated peripheral neuropathy and idiopathic bilateral vestibulopathy cohorts, in which RFC1 screening is increasingly recommended given non-trivial diagnostic yield (Neurology 2023, "Frequency and Phenotype of RFC1 Repeat Expansions in Bilateral Vestibulopathy," https://www.neurology.org/doi/10.1212/WNL.0000000000207553). - Motor neuron disease/ALS phenocopies — a German cohort study specifically screened MND-phenotype patients for biallelic RFC1 expansions (PMC11377604). - Parkinson's disease/atypical parkinsonism — recent 2025 work frames "Parkinson's disease and MSA [as] gateways to RFC1-related disorders," i.e., RFC1 expansion screening is now advocated within apparent idiopathic PD/MSA cohorts.

Screening: No population/newborn screening program (adult-onset, no early intervention available); carrier screening and cascade testing in relatives of an affected proband is appropriate once a family's specific pathogenic motif is known; prenatal and preimplantation genetic testing are technically available once the familial genotype is defined.

11. Outcome/Prognosis

  • Survival/mortality: Life expectancy does not appear to be reduced by RFC1 CANVAS/spectrum disorder — a key prognostic and counseling point, and a major discriminator from MSA (median survival ~9.3 years from onset in MSA vs. a much longer, non-life-limiting course in RFC1 disease).
  • Morbidity/function: Progressive disability trajectory — approximately 50% of patients require an assistive ambulatory device (e.g., cane) roughly 10 years after symptom onset; approximately 25% become wheelchair-dependent by ~15 years after onset. Falls risk is significant given combined sensory + vestibular + cerebellar deafferentation.
  • Quality of life: Substantially affected by chronic imbalance/fall risk, oscillopsia (which impairs reading/visual tasks during head movement), dysarthria/dysphagia in later stages, and the often years-long unexplained chronic cough that precedes diagnosis (with associated diagnostic-odyssey burden).
  • Complications: Falls and fall-related injury; aspiration risk from dysphagia; social/occupational impact of dysarthria and chronic cough.
  • Prognostic factors: No validated formal prognostic biomarker; loosely, larger repeat expansion size has been associated with earlier age of onset in some series, but no validated predictor of overall disease trajectory/severity exists. Ongoing natural-history/biomarker studies (e.g., the ARCA-registry-based global multicenter RFC1 natural history study) aim to establish quantitative outcome measures (SARA — Scale for Assessment and Rating of Ataxia; INAS — Inventory of Non-Ataxia Signs; CMTNS — Charcot-Marie-Tooth Neuropathy Score) for future trial readiness.

12. Treatment

No disease-modifying or curative treatment currently exists. Management is entirely multidisciplinary and symptomatic/supportive (per GeneReviews):

  • Ataxia: Physical and occupational therapy (balance/gait training, strengthening); adaptive mobility devices (canes, walkers, motorized wheelchairs); inpatient rehabilitation; home fall-prevention modification; weight management. (MAXO:0000011 physical therapy)
  • Vestibular dysfunction: Vestibular rehabilitation therapy — the standard of care for bilateral vestibular hypofunction generally; a CANVAS-specific case report on vestibular rehabilitation exists (ScienceDirect 2023, https://www.sciencedirect.com/science/article/pii/S167229302300048X). (MAXO term for vestibular/physical rehabilitation — verify exact MAXO ID)
  • Sensory neuropathy: Counseling on injury avoidance (given impaired proprioception/pain sensation); pain management rarely required.
  • Autonomic dysfunction: Symptomatic treatment of erectile dysfunction, urinary incontinence/retention, constipation/diarrhea, dry eyes/mouth. (MAXO:0000950 supportive care; NCIT:C15986 Pharmacotherapy as generic action term with appropriate therapeutic_agent)
  • Dysarthria: Speech-language therapy; augmentative/alternative communication as needed. (MAXO term for speech therapy — MAXO:0000930)
  • Dysphagia: Modified food consistency, videofluoroscopic/esophagographic evaluation, aspiration-risk assessment. (MAXO:0001351 occupational therapy / relevant swallowing-therapy term — verify)
  • Chronic cough: Proton pump inhibitors if reflux contributes; pulmonology/ENT referral for refractory neurogenic cough. (NCIT:C15986 Pharmacotherapy + appropriate therapeutic_agent for PPI, e.g., omeprazole)
  • Agents to avoid (iatrogenic worsening): Neurotoxic chemotherapy agents, high-dose pyridoxine, phenytoin, aminoglycosides, chronic alcohol use.

Investigational/experimental therapeutics: - Noisy galvanic vestibular stimulation and prosthetic vestibular implants are cited as promising investigational approaches for the bilateral vestibular hypofunction component (general bilateral vestibular weakness literature, Curr Treat Options Neurol 2026, https://link.springer.com/article/10.1007/s11940-026-00866-w), not yet CANVAS-specific approved therapies. - Mechanism-targeted small-molecule/G-quadruplex-ligand strategies: Structural biology work explicitly proposes that resolved G4 structures formed by pathogenic AAGGG repeats could guide rational design of small-molecule ligands or helicases to resolve the toxic secondary structure — a preclinical concept, not yet in trials (PMC10954463, PMC10563062). - No published antisense oligonucleotide (ASO), gene-replacement, or gene-editing clinical program was identified in this search for RFC1/CANVAS specifically (searches for ASO/gene therapy approaches returned no CANVAS-specific hits) — this remains an unmet therapeutic gap, consistent with the disease being explicitly described in the primary literature as "currently untreatable" (Science Advances 2024). - Natural history/biomarker study: A prospective global 2-year multicenter natural history study (ARCA registry, 31 centers) is underway to define clinical outcome measures and biomarkers in preparation for future interventional trials (Ataxia Global Initiative, https://ataxia-global-initiative.net/projects/rfc1-a-global-multicenter-multimodal-natural-history-clinical-outcome-and-biomarker-study-based-on-the-arca-registry/). The National Ataxia Foundation's CRC-SCA observational study also now includes RFC1 Ataxia/CANVAS as an eligible cohort.

Treatment strategy/algorithm: Sequential, symptom-triggered multidisciplinary referral (neurology, PT/OT, physiatry, speech-language pathology, respiratory/ENT, gastroenterology) with annual neurologic surveillance (or more frequently during acute change) using SARA and CMTNS as standardized outcome measures, per GeneReviews management/surveillance recommendations.

13. Prevention

  • Primary prevention: None available — this is a genetic, adult-onset disorder with no known modifiable environmental cause to intervene upon prior to disease onset.
  • Secondary prevention/early detection: Increasing clinical index of suspicion (screening idiopathic bilateral vestibulopathy, idiopathic chronic cough, and idiopathic late-onset ataxia/peripheral neuropathy cohorts for RFC1 expansions) shortens diagnostic delay and enables earlier supportive intervention/fall-prevention counseling, though it does not alter the underlying disease course given the absence of disease-modifying therapy.
  • Genetic/reproductive prevention: Genetic counseling for affected individuals, carriers, and at-risk relatives regarding autosomal recessive inheritance and pseudodominance; carrier testing of at-risk relatives once the familial pathogenic motif is known; prenatal testing and preimplantation genetic testing are technically available options for reproductive planning; DNA banking is recommended given the rapidly evolving assay landscape (RP-PCR → Southern blot → long-read sequencing).
  • Tertiary prevention: Avoidance of neurotoxic exposures (aminoglycosides, phenytoin, neurotoxic chemotherapy, high-dose pyridoxine, chronic alcohol) to prevent iatrogenic acceleration of neuropathy/cerebellar/vestibular injury in known or at-risk individuals; fall-prevention home modification; aspiration-risk mitigation for dysphagia.
  • Screening programs: No population-level or newborn screening program exists (late-onset disease); targeted cascade genetic screening within affected families is the practical current approach.

14. Other Species / Natural Disease

  • Naturally occurring disease in other species: No naturally occurring veterinary/wildlife CANVAS-like disease attributable to RFC1 was identified in the literature reviewed (no OMIA entry surfaced in this search). This appears to be a human-specific clinical entity as currently documented, likely reflecting both the specific human AluSx3-derived repeat locus (Alu elements are primate-specific transposons) and the recency of genetic characterization.
  • Orthologous gene: RFC1 is a broadly conserved gene across vertebrates (mouse Rfc1, zebrafish rfc1, and more distant orthologs in Drosophila and yeast, given its fundamental role in DNA replication/PCNA loading) — see NCBI Gene for ortholog records. No repeat-expansion equivalent is expected in these species since the pathogenic locus is a human/primate-specific Alu-derived repeat.
  • Comparative pathology/evolutionary conservation: The core RFC1 clamp-loader function is deeply conserved (yeast to human), underscoring why complete loss of function is developmentally lethal across species (see Section 15), while the CANVAS-causing repeat-expansion mechanism itself is a human-specific genomic event superimposed on this conserved gene.
  • Transmission/zoonotic potential: Not applicable — this is a genetic (non-infectious) human disease.

15. Model Organisms

  • Mouse: A conventional Rfc1 knockout allele (Jackson Laboratory Phenotyping Center / IMPC-type resource) is embryonic and/or pre-weaning lethal in the homozygous state, precluding straightforward modeling of the human disease (which is caused by a hypomorphic repeat-expansion allele, not complete null) via simple knockout. This lethality itself is informative: it underscores that the human CANVAS-causing repeat allele must be substantially hypomorphic/partial-function (or repeat-toxic-gain-of-function) rather than a complete null, since affected humans are viable into adulthood.
  • Zebrafish: To circumvent mouse embryonic lethality, a CRISPR/Cas9-generated zebrafish rfc1 loss-of-function model was developed. rfc1⁻/⁻ larvae are viable long enough (dying prematurely after ~10 days) to permit functional neurodevelopmental analysis. This model revealed a key developmental role for rfc1 in the expansion and differentiation of cerebellar granule and Purkinje cell neuronal progenitor pools (Nat Commun 2025, https://www.nature.com/articles/s41467-025-60775-5; PMC12217872) — informative for understanding baseline RFC1 neurodevelopmental biology, though it models complete loss-of-function rather than the repeat-expansion-specific toxic mechanism per se.
  • Drosophila: A neuronal RFC1 Drosophila model expressing the pathogenic AAGGG repeat demonstrated tissue-specific reduction in RFC1 transcript expression, impaired RFC1 function, and increased sensitivity to DNA damage — directly modeling the repeat-toxicity mechanism rather than simple gene knockout (per 2025 bioRxiv preprint, https://www.researchgate.net/publication/397733610).
  • Human iPSC-derived neurons (iNeurons): The most disease-relevant model to date. CANVAS patient fibroblast-derived iPSCs differentiated into neurons recapitulate defects in neuronal development and diminished synaptic connectivity; critically, CRISPR-mediated deletion of a single expanded (AAGGG) allele rescues these phenotypes, while simple re-expression of RFC1 protein does not rescue them — the key evidence for an RFC1-protein-independent, repeat-dependent toxic mechanism (Science Advances 2024, https://www.science.org/doi/10.1126/sciadv.adn2321; PMC11373605).
  • Model limitations: No current animal model fully recapitulates the adult-onset, multisystem (cerebellar + sensory ganglionopathy + vestibular + cough) human phenotype with the biallelic repeat expansion genotype in vivo; existing models variably capture (a) complete RFC1 loss-of-function developmental biology (mouse/zebrafish knockouts) or (b) repeat-specific molecular toxicity in a heterologous/reduced system (Drosophila, human iNeurons) — a genuine human-model-mismatch gap exists between repeat-toxicity cellular models and an in vivo repeat-expansion "knock-in" animal model reproducing the full adult neurodegenerative phenotype, which had not yet been reported as of the sources reviewed here.
  • Research applications: These models collectively support study of (1) normal RFC1 developmental neurobiology (granule/Purkinje progenitor expansion), (2) repeat-driven G-quadruplex/replication-stress toxicity, and (3) candidate therapeutic screening (e.g., G4-resolving small molecules, ASO/CRISPR repeat-targeting strategies) in a currently treatment-free disease.
  • Resources: MGI (mouse Rfc1 knockout phenotype data, IMPC), ZFIN (zebrafish rfc1 model), standard Drosophila stock/CRISPR resources, and patient-derived iPSC lines (institution-specific biobanks, not yet indexed in a large public repository per this search).

Summary Ontology Term Suggestions for KB Curation

  • Disease: MONDO:0044720; Orphanet ORPHA:504476; OMIM #614575
  • Gene: RFC1 (hgnc: — verify exact HGNC numeric ID before use, e.g. via uv run runoak -i sqlite:obo:hgnc info RFC1)
  • Key HP terms: HP:0001251 (Ataxia), HP:0007141/HP:0003474 (axonal sensory neuropathy features — verify most specific term for "sensory neuronopathy"), HP:0025406/vestibular dysfunction term (verify exact HPO ID), HP:0031246 (Chronic cough), HP:0001278 (Orthostatic hypotension), HP:0000639 (Nystagmus), HP:0007766 (Downbeat nystagmus), HP:0001260 (Dysarthria), HP:0002015 (Dysphagia), HP:0002380 (Fasciculations), HP:0001300 (Parkinsonism)
  • GO terms: GO:0006260 (DNA replication), GO:0006281 (DNA repair)
  • CL terms: dorsal root ganglion sensory neuron, Purkinje cell, vestibular ganglion neuron (verify exact CL IDs via OAK before curation)
  • UBERON terms: UBERON:0002037 (cerebellum), UBERON:0000044 (dorsal root ganglion), plus vestibular/trigeminal/facial ganglion terms (verify exact IDs)
  • MAXO terms: MAXO:0000011 (physical therapy), MAXO:0000950 (supportive care), MAXO:0000930 (speech therapy), NCIT:C15986 (Pharmacotherapy, for PPI/symptomatic drugs)

Important curatorial note (NEC risk): Given that "CANVAS" and "RFC1 disease" nomenclature has evolved rapidly (2019–2025) and overlaps phenotypically with MSA, SCA3, Friedreich ataxia, and idiopathic bilateral vestibulopathy, curators should verify the MONDO:0044720 gene/OMIM anchors (RFC1, OMIM #614575/*102579) against any deep-research output before use, per the project's Named Entity Confusion preflight protocol.

Sources